

No. 24-1365

**In the United States Court of Appeals
for the District of Columbia Circuit**

DOCTORS FOR DRUG POLICY REFORM; BRYON ADINOFF, DR.,

Petitioners

v.

DRUG ENFORCEMENT ADMINISTRATION; ANNE MILGRAM, IN HER OFFICIAL
CAPACITY AS ADMINISTRATOR OF THE UNITED STATES DRUG ENFORCEMENT
ADMINISTRATION,

Respondents

On Petition for Review of Orders of the Drug Enforcement Administration
(Oct. 28, 2024 and Nov. 25, 2024)

**PETITIONERS' APPENDIX
VOLUME 6 OF 6
App.1478 to App.1670**

Austin T. Brumbaugh
D.C. Circuit Bar No. 65727
YETTER COLEMAN LLP
811 Main Street, Suite 4100
Houston, Texas 77002
713-457-3099

Counsel for Petitioners

TABLE OF CONTENTS

DATE	DESCRIPTION	PAGE
	Orders and Rulings	
	Volume 1	
2024-12-06	Order Denying Motion to Stay	App.1
2024-10-28	Order Selecting Participants	App.7
2024-11-25	Bryon Adinoff, M.D. Rejection Letter	App.10
2023-08-29	Recommendation of the Department of Health and Human Services to the Drug Enforcement Administration	App.11
2024-04-11	Office of Legal Counsel Memorandum Opinion for the Attorney General, 48 Op. O.L.C. ____	App.261
2024-05-21	Notice of Proposed Rulemaking, 89 FR 44597-01	App.299
2024-08-29	Notice of Hearing on Proposed Rulemaking, 89 FR 70148-01	App.325
2024-09-26	Doctors for Drug Policy Reform Request to Participate in Hearing	App.327
2024-10-31	Preliminary Order	App.333
2024-11-19	Order re Standing, Scope, and Prehearing Procedures	App.343
2024-11-21	Order Denying Motion to Intervene	App.390
2024-12-04	Prehearing Ruling	App.394
2025-01-13	Order Regarding Village Farms International Hemp for Victory and OCO et al.'s Motion for Reconsider	App.404

DATE	DESCRIPTION	PAGE
	Requests to Participate and Agency Responses	
2024-02-28	Association of Federal Narcotics Agents Supporting Paper	App.411
2024-06-01	Request by International Academy on the Science and Impact of Cannabis	App.415
2024-06-04	Request by Khurshid Khoja (Greenbridge Corporate Counsel, P.C.	App.418
2024-06-11	Request by Sage Endoom Cannablisshum	App.423
2024-06-13	Request by Aubree Adams	App.431
2024-06-15	Request by Heidi Anderson-Swan	App.432
2024-06-16	Request by David Heldreth	App.473
2024-06-16	Request by National Drug & Alcohol Screening Association	App.443
2024-06-16	Request by Panacea Plant Sciences c/o David Heldreth	App.460
2024-06-17	Request by Bryn Spejcher	App.466
2024-06-17	Request by Ed Wood	App.467
	Volume 2	
2024-06-17	Request by Perkins Coie on behalf of American Trade Association for Cannabis and Hemp	App.498
2024-06-17	Request by Smart Approaches to Marijuana	App.500
2024-06-17	Request by Association of State Criminal Investigative Agencies	App.504
2024-06-18	Request by Association of Federal Narcotics Agents	App.507

DATE	DESCRIPTION	PAGE
2024-06-18	Request by Cannabis Industry Victims Educating Litigators	App.508
2024-06-18	Request by Coalition for Patient Rights	App.510
2024-06-19	Request by Bryan Krumm	App.526
2024-06-19	Request by Former DEA Administrators	App.536
2024-06-19	Request by Minority Cannabis Business Association	App.538
2024-06-19	Request by Phillip Drum	App.540
2024-06-19	Request by Tennessee Bureau of Investigation	App.542
2024-06-19	Request by United Empowerment Party	App.544
2024-06-20	Request by Doctors for Drug Policy Reform	App.548
2024-06-20	Request by Devan Maurice Dupuis and Nicholas Barreto	App.593
2024-06-20	Request by Lori Robinson	App.597
2024-06-20	Request by National Transportation Safety Board	App.599
2024-06-20	Request by South Carolina Attorney General and Various Other Attorneys General	App.601
2024-06-20	Request by United States Cannabis Coalition	App.604
2024-06-26	Request by Nicole Ricci	App.606
2024-07-19	Request by University of California San Diego Center for Medicinal Cannabis Research	App.611
2024-08-26	Request by Shane Gallichio	App.612
2024-08-29	Request by Brian Austin	App.613

DATE	DESCRIPTION	PAGE
2024-08-29	Request by Cris Ericson	App.614
2024-08-29	Request by Prince Lobel Strategic Advisors	App.623
2024-08-30	Request by Roneet Lev, MD - HighTruths.com and International Academy of Science and Impact of Cannabis	App.625
2024-08-30	Supplement by National Transportation Safety Board	App.626
2024-09-03	Request by International Association of Chiefs of Police	App.631
2024-09-04	Request by Sandra Rapke	App.634
2024-09-06	Request by Community Anti-Drug Coalitions of America	App.635
2024-09-07	Request by Mariah Ashley Magnuson	App.637
2024-09-09	Request by Kelly Anderson	App.642
2024-09-11	Request by Hemp for Victory	App.643
2024-09-11	Request by Jim Fricke for The Plant Counsel	App.664
2024-09-12	Request by Daniel Kyle	App.665
2024-09-12	Request by Grayson Lichtenthaler	App.667
2024-09-12	Request by Joshua Taylor	App.668
2024-09-12	Request by Justin Taylor	App.669
2024-09-12	Request by Wei He, Ph.D.	App.670
2024-09-14	Request by Jordan Zito	App.673
2024-09-16	Request by Panacea Plant Sciences c/o David Heldreth	App.674
2024-09-16	Request by David Heldreth	App.681

DATE	DESCRIPTION	PAGE
2024-09-16	Request by Emily Fisher, CEO, Leafwell, Inc.	App.688
2024-09-17	Request by August Wakat	App.689
2024-09-18	Request by American Academy of Child and Adolescent Psychiatry	App.690
	Volume 3	
2024-09-18	Request by Bryn Spejcher	App.691
2024-09-18	Supplement by Phillip Drum	App.715
2024-09-20	Request by Cannabis Law PA	App.720
2024-09-20	Request by Drug Enforcement Association of Federal Narcotics Agents	App.723
2024-09-20	Request by Minorities for Medical Marijuana	App.724
2024-09-22	Request by Derek Shirley	App.740
2024-09-23	Request by Drug Enforcement Association of Federal Narcotics Agents	App.742
2024-09-23	Request by Bryan Krumm	App.744
2024-09-23	Request by Pharmacists Cannabis Coalition of California	App.754
2024-09-24	Request by The Doc App	App.756
2024-09-25	Supplement by Aubree Adams	App.758
2024-09-25	Supplement by Aubree Adams	App.761
2024-09-25	Request by Curio Wellness	App.771
2024-09-25	Request by Heidi Anderson	App.775

DATE	DESCRIPTION	PAGE
2024-09-25	Request by Veterans Action Council	App.786
2024-09-26	Request by Bryon Adinoff, M.D. and Doctors for Drug Policy Reform with CV	App.790
2024-09-26	Request by Michael Krawitz	App.839
2024-09-26	Request by MedPharm	App.841
2024-09-26	Supplement by University of California San Diego Center for Medicinal Cannabis Research	App.902
2024-09-27	Request by Ariana Fleishman	App.904
2024-09-27	Request by Cynthia Mateo	App.905
2024-09-27	Request by Etienne Fontan	App.906
2024-09-27	Request by Ian Patrick Patriarca	App.909
2024-09-27	Request by Jessica Garza	App.910
2024-09-27	Request by Jonathan Frank	App.911
2024-09-27	Request by Rafael Acevedo	App.912
2024-09-27	Request by The Commonwealth Project	App.913
2024-09-27	Request by Vicente LLP by Timothy D. Swain	App.915
2024-09-29	Request by Kai Hoffman	App.933
2024-09-29	Request by Kainan Boring	App.944
2024-09-29	Request by Keila Castillo	App.945
2024-09-29	Request by Kym Silva	App.948
2024-09-29	Request by Lilly Tirado	App.949

DATE	DESCRIPTION	PAGE
2024-09-30	Request by American Academy of Hospice and Palliative Medicine	App.950
2024-09-30	Request by American Psychological Association	App.952
2024-09-30	Request by Andrew DeAngelo	App.954
2024-09-30	Request by Ari Kirshenbaum, PhD	App.958
	Volume 4	
2024-09-30	Request by Association of American Railroads	App.959
2024-09-30	Request by BayMedica, LLC and Greenbridge Corporate Counsel, P.C.	App.960
2024-09-30	Request by Coalition for Patient Rights	App.973
2024-09-30	Request by Coss Marte	App.975
2024-09-30	Request by Compassion Center by Stormy Ray	App.976
2024-09-30	Request by Dennis Schuller	App.978
2024-09-30	Request by Drug Policy Alliance by Cat Packer	App.979
2024-09-30	Request by Ellen Brown	App.982
2024-09-30	Request by Erin Kirk	App.983
2024-09-30	Request by Esaia Gonzalez	App.984
2024-09-30	Request by Green Thumb Industries Inc.	App.988
2024-09-30	Request by Jasmine Montoya	App.1050
2024-09-30	Request by Jason Greninger	App.1054
2024-09-30	Request by Jordan Smith	App.1056

DATE	DESCRIPTION	PAGE
2024-09-30	Request by Karen O’Keefe	App.1057
2024-09-30	Request by Khurshid Khoja and BayMedica	App.1077
2024-09-30	Request by Last Prisoner Project	App.1090
2024-09-30	Request by Michael Doyle	App.1096
2024-09-30	Request by Natalie P. Hartenbaum, MD, MPH	App.1098
2024-09-30	Request by National Cannabis Industry Association	App.1104
2024-09-30	Request by National Sheriffs Association	App.1108
2024-09-30	Request by Nicholas Barreto	App.1112
2024-09-30	Request by Nick Richards, GreenspoonMarder	App.1116
2024-09-30	Request by National Organization for the Reform of Marijuana Laws (NORML)	App.1120
2024-09-30	Request by New York Office of Cannabis Management	App.1163
2024-09-30	Request by Patrick Oglesby	App.1171
2024-09-30	Request by Perkins Coie on behalf of American Trade Association for Cannabis and Hemp	App.1174
2024-09-30	Request by RTI International	App.1374
2024-09-30	Request by Russell Palmer	App.1374
	Volume 5	
2024-09-30	Request by Sensible Colorado	App.1380
2024-09-30	Request by Sisley Research Institute	App.1424
2024-09-30	Request by State of Colorado	App.1427

DATE	DESCRIPTION	PAGE
2024-09-30	Request by State of Nebraska	App.1430
2024-09-30	Request by Steph Sherer for Americans for Safe Access Foundation	App.1434
2024-09-30	Request by Stephen Mandile	App.1436
2024-09-30	Request by Students for Sensible Drug Policy	App.1437
2024-09-30	Supplement by Drug Enforcement Association of Federal Narcotics Agents	App.1440
2024-09-30	Request by T. Christopher Wright	App.1442
2024-09-30	Supplement by Tennessee Bureau of Investigation	App.1444
2024-09-30	Request by Training Marbles, Inc.	App.1447
2024-09-30	Request by United States Cannabis Coalition	App.1449
2024-09-30	Request by Village Farms International Inc.	App.1452
2024-10-08	Request by Walt A. Sanders	App.1458
2024-10-09	Request by Jeffrey Faatz	App.1460
	Request by Cannabis Bioscience International Holdings	App.1461
	Request by Equity Trade Network	App.1464
	Request by Jahan Marcu	App.1466
	Request by Kenneth Finn	App.1468
	Request by Michael Rountree	App.1472
	Request by Patrick Oglesby	App.1475

DATE	DESCRIPTION	PAGE
	Volume 6	
	State of Wisconsin vs Bloom 2020 CPS	App.1478
	Request by Tim McKibben	App.1502
	Request by Shanetha Lewis	App.1505
2024-09-10	Aubree Adams Cure Letter	App.1509
2024-09-10	Bryn Spejcher Cure Letter	App.1510
2024-09-10	Darwin Richardson Cure Letter	App.1511
2024-09-10	Tennessee Bureau of Investigation Cure Letter	App.1512
2024-09-10	Drug Enforcement Association of Federal Narcotics Agents Cure Letter	App.1513
2024-09-10	Heidi Anderson-Swan Cure Letter	App.1514
2024-09-10	Khursid Khoja Cure Letter	App.1515
2024-09-10	Lori Robinson Cure Letter	App.1516
2024-09-10	Michael Rountree Cure Letter	App.1517
2024-09-10	Minority Cannabis Business Association Cure Letter	App.1518
2024-09-10	Phillip Drum Cure Letter	App.1519
2024-09-10	University of California San Diego Center for Medical Cannabis Research Cure Letter	App.1520
2024-10-28	American Academy of Child Rejection Letter	App.1521
2024-10-28	American Academy of Hospice & Palliative Medicine Acceptance Letter	App.1522

DATE	DESCRIPTION	PAGE
2024-10-28	Ari Kirshenbaum Acceptance Letter	App.1523
2024-10-28	Aubree Adams Rejection Letter	App.1524
2024-10-28	BayMedica, LLC Rejection Letter	App.1525
2024-10-28	Bryn Spejcher Rejection Letter	App.1526
2024-10-28	Cannabis Industry Victims Educating Litigators Acceptance Letter	App.1527
2024-10-28	Cannabis Law PA (Attn: Judith Cassel) Rejection Letter	App.1528
2024-10-28	Cannabis Law PA (Attn: Micah Bucy) Rejection Letter	App.1529
2024-10-28	Community Anti-Drug Coalitions of America Acceptance Letter	App.1530
2024-10-28	Corey Burchman, M.D. (Hemp for Victory) Acceptance Letter	App.1531
2024-10-28	Curio Wellness Rejection Letter	App.1532
2024-10-28	Darinia Douchi, M.D. (Hemp for Victory) Acceptance Letter	App.1533
2024-10-28	Drug Enforcement Association of Federal Narcotics Agents Acceptance Letter	App.1534
2024-10-28	Ellen Brown Acceptance Letter	App.1535
2024-10-28	Erin Kirk Acceptance Letter	App.1536
2024-10-28	Full Spectrum Inc. Rejection Letter	App.1537
2024-10-28	Heidi Anderson-Swan Rejection Letter	App.1538
2024-10-28	International Academy on the Science & Impact of Cannabis Acceptance Letter	App.1539

DATE	DESCRIPTION	PAGE
2024-10-28	International Association of Chiefs of Police Acceptance Letter	App.1540
2024-10-28	Jahan Marcu Rejection Letter	App.1541
2024-10-28	Jason Castro Rejection Letter	App.1542
2024-10-28	Jeffrey Fatz Rejection Letter	App.1543
2024-10-28	John Jones, Cannabis Bioscience International Holdings Acceptance Letter	App.1544
2024-10-28	Kenneth Finn, MD Acceptance Letter	App.1545
2024-10-28	Natalie Hartenbaum Rejection Letter	App.1546
2024-10-28	National Cannabis Industry (Aaron Smith) Acceptance Letter	App.1547
2024-10-28	National Cannabis Industry (Michelle Rutter) Acceptance Letter	App.1548
2024-10-28	National Drug & Alcohol Screening Association Acceptance Letter	App.1549
2024-10-28	National Sheriff's Association Acceptance Letter	App.1550
2024-10-28	National Transportation Safety Board Acceptance Letter	App.1551
2024-10-28	Pharmacists' Cannabis Coalition of California Rejection Letter	App.1552
2024-10-28	Phil Molloy Rejection Letter	App.1553
2024-10-28	Phillip Drum Acceptance Letter	App.1554
2024-10-28	Prince Lobel Strategic Rejection Letter	App.1555
2024-10-28	Robert Head (Hemp for Victory) Acceptance Letter	App.1556

DATE	DESCRIPTION	PAGE
2024-10-28	Sandra Rapke Rejection Letter	App.1557
2024-10-28	Shanetha Lewis Acceptance Letter	App.1558
2024-10-28	Smart Approaches to Marijuana Acceptance Letter	App.1559
2024-10-28	State of Nebraska Acceptance Letter	App.1560
2024-10-28	Synthcon LLC Rejection Letter	App.1561
2024-10-28	Tennessee Bureau of Investigation Acceptance Letter	App.1562
2024-10-28	Teresa Simon Rejection Letter	App.1563
2024-10-28	The Commonwealth Project Acceptance Letter	App.1564
2024-10-28	The Doc App Acceptance Letter	App.1565
2024-10-28	Victor Bohm (Hemp for Victory) Acceptance Letter	App.1566
2024-10-28	Village Farms International Inc. Acceptance Letter	App.1567
2024-10-28	Wei He Rejection Letter	App.1568
2024-11-25	American Psychological Association Rejection Letter	App.1569
2024-11-25	American Trade Association for Cannabis Rejection Letter	App.1570
2024-11-25	Americans for Safe Access Foundation Rejection Letter	App.1571
2024-11-25	Andrew DeAngelo Rejection Letter	App.1572
2024-11-25	Andrew Kline Rejection Letter	App.1573
2024-11-25	Ariana Fleishman Rejection Letter	App.1574
2024-11-25	Association of American Railroads Rejection Letter	App.1575

DATE	DESCRIPTION	PAGE
2024-11-25	Association of State Criminal Investigative Agencies Rejection Letter	App.1576
2024-11-25	August Wakat Rejection Letter	App.1577
2024-11-25	Brian Austin Rejection Letter	App.1578
2024-11-25	Bryan Krumm Rejection Letter	App.1579
2024-11-25	Bryon Adinoff Rejection Letter	App.1580
2024-11-25	Catherine Bloom Rejection Letter	App.1581
2024-11-25	Coalition for Patients Rights Rejection Letter	App.1582
2024-11-25	Con Body Rejection Letter	App.1583
2024-11-25	Cris Ericson Rejection Letter	App.1584
2024-11-25	Cynthia Mateo Rejection Letter	App.1585
2024-11-25	Daniel Kyle Rejection Letter	App.1586
2024-11-25	David Heldreth Jr. Rejection Letter	App.1587
2024-11-25	Dennis Schuller Rejection Letter	App.1588
2024-11-25	Derek J. Shirley Rejection Letter	App.1589
2024-11-25	Devan Maurice Dupuis Rejection Letter	App.1590
2024-11-25	Dominique Mendiola Rejection Letter	App.1591
2024-11-25	Drug Policy Alliance Rejection Letter	App.1592
2024-11-25	Ean Seeb Rejection Letter	App.1593
2024-11-25	Ed Wood Rejection Letter	App.1594
2024-11-25	Emily Fisher Rejection Letter	App.1595

DATE	DESCRIPTION	PAGE
2024-11-25	Grayson Lichtenthaler Rejection Letter	App.1596
2024-11-25	Greenspoon Marder, LLP Rejection Letter	App.1597
2024-11-25	Ian Patrick Patriarca Rejection Letter	App.1598
2024-11-25	Jasmine Montoya Rejection Letter	App.1599
2024-11-25	Jessica Garza Rejection Letter	App.1600
2024-11-25	Jonathan Frank Rejection Letter	App.1601
2024-11-25	Jordan Christopher Zito Rejection Letter	App.1602
2024-11-25	Jordan Smith Rejection Letter	App.1603
2024-11-25	Joseph Garofalo Rejection Letter	App.1604
2024-11-25	Joshua Taylor Rejection Letter	App.1605
2024-11-25	Julie Monteriro Rejection Letter	App.1606
2024-11-25	Justin J. Taylor Rejection Letter	App.1607
2024-11-25	Kai Hoffman Rejection Letter	App.1608
2024-11-25	Kainan Boring Rejection Letter	App.1609
2024-11-25	Keila E. Castillo Rejection Letter	App.1610
2024-11-25	Keith G. Freeman Rejection Letter	App.1611
2024-11-25	Kym Silva Rejection Letter	App.1612
2024-11-25	Last Prisoner Project Rejection Letter	App.1613
2024-11-25	Lilly Tirado Rejection Letter	App.1614
2024-11-25	Lori Robinson Rejection Letter	App.1615
2024-11-25	Major Cities Chiefs Association Rejection Letter	App.1616

DATE	DESCRIPTION	PAGE
2024-11-25	Major County Sheriffs of America Rejection Letter	App.1617
2024-11-25	Mariah Ashley Magnuson Rejection Letter	App.1618
2024-11-25	Marijuana Policy Project Rejection Letter	App.1619
2024-11-25	Michael Doyle Rejection Letter	App.1620
2024-11-25	Michael Krawitz Rejection Letter	App.1621
2024-11-25	Michael Rountree Rejection Letter	App.1622
2024-11-25	Minorities for Medical Marijuana, Inc. Rejection Letter	App.1623
2024-11-25	Minority Cannabis Business Association Rejection Letter	App.1624
2024-11-25	National Alliance of State Drug Enforcement Agencies Rejection Letter	App.1625
2024-11-25	National Association of Police Organizations Rejection Letter	App.1626
2024-11-25	National District Attorneys Association Rejection Letter	App.1627
2024-11-25	National HIDTA Directors Association Rejection Letter	App.1628
2024-11-25	National Narcotic Officers' Associations' Coalition Rejection Letter	App.1629
2024-11-25	National Organization for the Reform of Marijuana Laws (NORML) Rejection Letter	App.1630
2024-11-25	New York Office of Cannabis Management Rejection Letter	App.1631
2024-11-25	Nicholas Barreto Rejection Letter	App.1632

DATE	DESCRIPTION	PAGE
2024-11-25	Nicole Ricci Rejection Letter	App.1633
2024-11-25	Patrick Oglesby Rejection Letter	App.1634
2024-11-25	Perkins Coie Rejection Letter	App.1635
2024-11-25	Perkins Coie on behalf of Green Thumb Industries Inc. Rejection Letter	App.1636
2024-11-25	Perkins Coie on behalf of MedPharm Rejection Letter	App.1637
2024-11-25	Perkins Coie on behalf of MedPharm Rejection Letter	App.1638
2024-11-25	Perkins Coie on behalf of MedPharm Rejection Letter	App.1639
2024-11-25	Rafael Acevedo Rejection Letter	App.1640
2024-11-25	RTI International Rejection Letter	App.1641
2024-11-25	Russell Palmer Rejection Letter	App.1642
2024-11-25	Sage Endoom Cannablisshum Rejection Letter	App.1643
2024-11-25	San Diego County Rejection Letter	App.1644
2024-11-25	Sensible Drug Policy Rejection Letter	App.1645
2024-11-25	Sergeants Benevolent Association Rejection Letter	App.1646
2024-11-25	Shane Gallichio Rejection Letter	App.1647
2024-11-25	Shane Pennington Rejection Letter	App.1648
2024-11-25	State of Colorado Rejection Letter	App.1649
2024-11-25	Stephen J. Mandile Rejection Letter	App.1650
2024-11-25	Students for Sensible Drug Policy Rejection Letter	App.1651
2024-11-25	Suzanne Sisley, M.D. Rejection Letter	App.1652

DATE	DESCRIPTION	PAGE
2024-11-25	T. Christopher Wright Rejection Letter	App.1653
2024-11-25	The Equity Trade Network Rejection Letter	App.1654
2024-11-25	The Plant Counsel Rejection Letter	App.1655
2024-11-25	The Veterans Action Council Rejection Letter	App.1656
2024-11-25	Thomas J. Tobin Rejection Letter	App.1657
2024-11-25	Training Marbles, Inc. Rejection Letter	App.1658
2024-11-25	United Empowerment Party Rejection Letter	App.1659
2024-11-25	United States Cannabis Coalition Rejection Letter	App.1660
2024-11-25	Veterans Action Council Rejection Letter	App.1661
2024-11-25	Veterans Action Council Rejection Letter	App.1662
2024-11-25	Veterans Action Council Rejection Letter	App.1663
2024-11-25	Vicente LLP on behalf of Sensible Colorado Rejection Letter	App.1664
2024-11-25	Vicente LLP Rejection Letter	App.1665
	University of California San Diego's Center for Medicinal Cannabis Rejection Letter	App.1666
2024-11-27	Draft letters document listing by Heather E. Achbach	App.1667

Dated: February 17, 2025

Respectfully submitted,

/s/Austin T. Brumbaugh

Austin T. Brumbaugh

D.C. Circuit Bar No. 65727

YETTER COLEMAN LLP

811 Main Street, Suite 4100

Houston, Texas 77002

713-457-3099

Attorney for Petitioners

41

ZACH & KATIE, married June 30, 2012



Katie and Zach both began their professional careers working at Northwestern Mutual in the mid 2000's, Katie as a life insurance underwriter and Zach as a trader. They met in 2010 when they were both volunteering at Unity in Motion, a nonprofit supporting disadvantaged children in Milwaukee. After volunteering as tutors for some time, Katie became

the board secretary and Zach the treasurer. After a whirlwind romance walking, talking, and laughing through the streets of Shorewood after long days at the office, they married in June 2012 at Lake Park Bistro where Zach proposed. That fall, Zach earned his CFA (Chartered Financial Analyst), one of the highest distinctions in the investment management profession. They welcomed their first child, Molly, just before their first wedding anniversary. One week after Molly was born, Zach graduated with his masters in applied economics from Marquette. They moved to Cedarburg in hopes of raising their children with similar close neighborhood vibes of their own childhoods. Shortly after, Robbie was born. Katie left her job at NM, when her salary wasn't much more than the cost of daycare, to stay at home and is so grateful to have had this time with them when they were so young. Her passion is special education advocacy, providing support to other burned out moms and enhancing community through the network of extraordinary and supportive providers we have built throughout the years. In her spare time she enjoys nature, reading, music, and making meals for friends. Zach has remained at Northwestern Mutual for over fifteen years and is now a director. He has become quite a handyman and woodworker and has lovingly restored the kids swingset, and built Molly a custom lemonade stand from scratch, among many other impressive projects. In his spare time he enjoys making memories via special events with his kids, bonding with his family, baseball, and playing guitar. Together, Zach and Katie enjoy spending time with their families, traveling, taking art classes, attending live music events and basking in mother nature's glory at their cabin in Mountain, WI.

5

MOLLY, born May 6 2013



Molly fulfilled Katie's lifelong dream of becoming a mother. She was the most easy-going baby in the world, so much so that Katie and Zach thought they had parenting figured out when she was 9 months old and decided to have another. She was developmentally behind in early pediatric milestones, but otherwise healthy and so happy. In March 2017 she gave us a scare when she had about 8 seizures in 12 hours. She was hospitalized at Children's hospital and discharged a few days later with little answers and prescriptions for seizure meds. A few months later we received results of genetic testing from her hospitalization and learned

that she has 16p11.2 microdeletion (missing a piece of her 16th chromosome) which resulted in seizure disorder, global delays, and a diagnosis on the spectrum (highly functioning). Molly has been seizure free since 2017 and off all seizure meds since 2020. She quickly wins the hearts of those she meets, is hilarious and has more empathy than most adults. Molly is thoughtful, kind, creative, and always considerate of others. Her acts of empathy and care towards others are demonstrations of kindness that make her mama's heart so proud. She excels at school and delights in events with her girl scout troop. Molly loves to swim, read, play the piano, craft, and play dolls. She is an especially talented artist, and frequently has masterpieces scattered throughout our house. Molly is a rule follower, a people pleaser, and asked for permission to say the girl scout pledge before bed. She cooks and dances with mama, and plays video games with daddy and challenges both parents to obstacle courses on the regular. As the big sister to a special needs brother, she has become accustomed to her needs often falling secondary and has the patience of a saint. She has little resentment and continues to love and support her brother endlessly. Our biggest domestic dispute is over sharing the spotify account.

ROBBIE, born Nov 21 2014



Named after the church where his parents were married, Robbie was a peaceful, contentful baby and a mama's boy from day one. After his first birthday, he was beginning to exhibit behaviors of autism and was referred by our pediatrician to a wonderful neuropsychologist, Dr Laughlin, who diagnosed him in 2017. One of the greatest gifts as his mother is the incredible, vast network of specialists and providers who have won our hearts and taught us how to do life. He began ABA (applied behavior analysis) therapy in our home when he was only two and a half. This consists of behavioral therapists following him around and often provoking him up to 40 hours a

week. He began public education at the age of three, and in 2019 switched ABA providers to InBloom. Day after day, he demonstrates his grace, patience, resilience and his brilliance as he thrives in a world that wasn't made for him. Robbie has struggled with extreme sensory aversions, struggles with crowds and has auditory sensitivities, dietary aversions, self-injurious behaviors like head-banging during periods of dysregulation, and incontinence issues. We have modified our home to adapt to his safety and sensory needs. We've only broken one bone (he removed the cast all by himself a few days later earning himself a much longer, more obtrusive cast), and we've had periods of being frequent fliers at Children's Hospital ER. At the current age of eight years old, he remains nonverbal and has established methods of communication with the few people closest to him to get his physical and emotional wants and needs met, and in 2019 Robbie received an AAC device (augmentative and alternative communication). Once Robbie's school speech pathologist, Lori Przybla, even traveled to Madison so she could train his entire team at Westlawn school, they are always going above and beyond for our kids. Robbie is an expert in all things animals, and new favorite hobby is to soak in mom and dad's new hot tub which now holds a kid friendly temp of 88 degrees. He is a fish and in general will joyfully swim in any body of water nearby. Robbie has perfect pitch and is constantly wow'ing us with his piano skills. He crushes hard on Sara Bareilles live piano videos, jams to Bob Marley & Led Zepplin, loves to make silly games up with his people and is generally a gift to anyone he meets.

SUSAN DELLUTRI, LLC

1661 N Water St, Suite 413
Milwaukee, WI 53202
www.SusanDellutri.com
SusanDellutri@SusanDellutri.com
414-207-4107

9/16/2023

Michael Hart
735 N Water Street, Suite 1212
Milwaukee, WI 53202

Re: Catherine (Katie) M Bloom

To whom it may concern,

My client, Catherine (Katie) M Bloom has signed the HIPAA compliant release, which I have attached for you, so that I can share my clinical experience and opinions of working with Katie since June 17, 2003.

I am a Wisconsin Licensed Clinical Social Worker (3177-123), Licensed Marriage and Family Therapist (430-124), Clinical Substance Abuse Counselor (2054-132), and American Association of Marriage and Family Therapist Approved Supervisor working in the field for just over thirty years. I have worked with Katie on and off for 18 years.

I began treating Katie 6/17/03 when she was 23 years old for Post Traumatic Stress Disorder over multiple independent, traumatic and difficult events including having been raped in high school and twice in college, biological and adopted family of origin issues, and circumstances surrounding the death of a close friend. She struggled with depression, anxiety, flashbacks, increased metabolic arousal, weight loss of 30 lbs, somatic distress, and behavioral efforts to avoid these highly charged thoughts and feelings. At that time she had used pot a couple times in her life and drank from time to time, reporting that she had drank more when she was in college. She did not make criteria for alcohol or other drug abuse or dependency at that time. Katie saw a doctor for antidepressant medication, followed treatment plans and did well working with her issues.

Katie returned to counseling 8/21/07 struggling with daily alcohol use, depression, anxiety, and mood swings. She met criteria for Alcohol dependence. We attempted outpatient treatment for her alcoholism but soon decided that she needed a higher level of care. She agreed to sign up for a 28 day inpatient alcohol treatment program. Upon her return from treatment, we worked on early recovery issues, developing her "program" to stay clean, and delved more deeply

judge didn't read prior to sentencing

- opens to current date in file!
She wrote late 2020 (if at all)

Admitted @
sentencing hearing
he had not
reviewed

8

into processing and healing her past traumas and family issues. She gained in skill in working with her emotions, relationships, goals, and boundaries. Her case was closed 1/14/09 noting that "the client did very well with inpatient AODA treatment, aftercare, weekly counseling, and AA."

September 23, 2013, the client returned to counseling having been clean and sober since her treatment in 2007. She was married 1 year with a 4 month old baby and came in for issues around managing and juggling relationships, carrying mortgages, working, having a baby, and extended family. On average, she came in 4-7 times a year always successfully using realizations and plans discovered in treatment to grow, manage, and create a her life and a good family environment.

Unfortunately, as time went on it became apparent that something was wrong with both of her children and she struggled to find anyone who could help her and her children. Ultimately, both her children were diagnosed with autism, her son severe, and her daughter having the additional burden of a significant seizure disorder. Initially devastated by the diagnosis, Katie was ultimately relieved that she could now find help. She went to work to learn all she could about severe autism, treatment, and to create a safe home and community environment, all the while taking care of her children who need assistance 24/7. The recommended treatment for both her children's autism included having a provider shadowing them in her home for as much as 40 hours a week. This treatment is state of the art treatment for her children but an adjustment for her and her family to have two providers supporting and sometime provoking her children day in and day out, week after week.

Katie could no longer work, or socialize like most other mothers can from time to time. Her husband works very hard to pay for the treatment, equipment, and the long term care that his children will require. In my work with Katie, I saw her over and over again handle with grace and a positive attitude the newest complications like head banging, feces smearing, not sleeping, broken bones, and long lasting emotional outbursts at the smallest provocation of change, texture, sound, etc. In many sessions, I processed with her the struggle, heartbreak, and feelings of abandonment around not getting help from family, friends, or sitters as most people didn't understand the pressure of non-stop 24/7 care or how to handle special needs children. At times she could find respite in swapping a couple hours with other exhausted mothers of special needs children.

10

In April of 2018, the client reported that she had used marijuana a couple times to reduce her stress level mid day or to sleep during the few hours her kids were not awake in the night. She reported that her doctor prescribed for her Xanax, a highly addictive, powerful benzodiazepine tranquilizer, but they made her too drowsy to be vigilant of her special needs children's every move, juggle the children's therapy schedules, and just manage all the other things that a home and family require. She came in wanting to discuss if this would threaten her sobriety from alcohol since 2007. This is not a behavior seen in a person having a relapse. We discussed at length the potential risks, what to watch for, and created a plan that she could use to know that she was increasing in tolerance, frequency, denial, rationalization, and loss of control. She came in, on her own, more frequently in 2018 to monitor her minimal, medicinal marijuana use. On 10/10/18, we discussed her pot use again at length. She reported using 1.5 ounces per month, never more, zero drug seeking feelings or behaviors, a reduction in her anxiety, getting her work done, being organized, and her mother and best friend were abreast of her use, etc. The session ended with the client agreeing to cut back that week just to assure her was still medicinal.

She did not return to therapy until 2/27/20 when she came in to report that she could feel herself wanting more marijuana to deal with the great stress she was under so she had quit on 1/20/20. We continued to meet about once a month around her stress in managing the kids, home, changing care givers, school possibilities, constant emergencies and medicals issues for herself and the kids, and no one being willing or able to help. Although, she did not tell me that she had returned to marijuana use and learned how to reduce and then control the dose by using the marijuana infused coconut oil to make edibles, she continued exhibit use meditation, prayer, acceptance, connecting with other mothers of special needs kids, juggling, organizing, and growing. She cut back on her son's therapy to find a way that the family could spend fun time together by going to a cabin. Her functioning could be easily seen in what she was managing, organizing, creating, and how she was processing with me her realizations, pain, growth, and attitude. In her last session before the event in question we spent time processing how she was able to figure out how to get her son through emergency dental surgery without an uncontrollable outburst and biting. We highlighted her strength and skill. She was able to see how life had prepared her for this. We also discussed how she could continue to give Molly the attachment and attention that she needs too.

Since this event, Katie has returned to counseling every other week along with AA and meeting her sponsor. She has attended and worked in earnest in all of our sessions looking at how she got here, the effects of her behavior on her children and husband, guilt, fear, anxiety, and regret. She has especially struggled with the attachment trauma, fear, dysregulation, and regression that her children experienced being taken by CPS and the extended separation from her, and the impact that this could have on her husband's ability to provide for their children's lifetime. However, true to her form and history, she has also begun to see the silver lining, learn from the lessons, focus on gratitude, and surrender to her higher power and life. She has also gotten the attention of family members and is now receiving much appreciated support and respite.

After working with Katie for 18 years, I can tell you with certainty that Katie is a high functioning, attentive, present mother even under unusually demanding circumstances that will likely last her life time. I have walked the path with her and have witnessed her recovering from multiple traumas, complex relational trauma, and alcohol addiction. I have worked with countless addicts and drug dealers of all sorts over my 30 year career, and Katie's situation is not that. She does not have tell tail or subtle the signs, symptoms, or behaviors of a person actively addicted to marijuana or dealing. This is a devastating case of inaccurate projection of criminal intent onto an exhausted but high functioning mother and wife who carefully used marijuana medically to cope with an untenable situation.

Respectfully,

Susan Dellutri, LCSW, LMFT, CSAC

Judge didn't
read prior to
Sentencing
(if at all)
told us @ beginning
of hearing

12

Kelly Theodore, APNP
930 E. Knapp Street Suite 34
Milwaukee, WI 53202
414.671.9355
Tulayawellness@gmail.com

March 5, 2021

Attorney Michael Hart
735 N Water Street #1212
Milwaukee WI 53202

Dear Attorney Hart,

I am writing on behalf of my patient, Catherine Bloom, who I have seen for psychiatric medication management since October 2020. Prior to meeting with me, Ms. Bloom's psychotropic medication, citalopram, was managed by her Primary Care Physician. Ms. Bloom established care with me seeking help for severe anxiety symptoms. She has a history of severe sexual trauma that she continues to engage in therapy for. She has been treated with medications such as citalopram and Xanax however these were not fully effective. The Xanax was only utilized a few times as it significantly interfered with her ability to care for her children. It was at this point that she began utilizing marijuana to help treat her anxiety. The marijuana relieved her debilitating anxiety enough to attend to the 24/7 needs of her children without severely reducing her ability to function.

She sought treatment with me, a psychiatric nurse practitioner, with the hopes of initiating a medication regimen that would aid in treatment of her symptoms. I added quetiapine twice daily to help with anxiety and insomnia symptoms which has been very effective. During our therapeutic relationship, I have come to know Ms. Bloom as an extremely caring and dedicated mother. She has been honest in her engagement, she understands the gravity of her charges and has demonstrated sincere remorse for the choices that she has made. Ms. Bloom is a dedicated mother, who quit her job to help support the needs of her two young special needs children; one with severe non-verbal autism, manifested by head banging, safety awareness, sleep disruption, and feces smearing, and her other child who has seizures, emotional and cognitive delays because of a chromosomal abnormality.

Ms. Bloom's adherence to her medications, continued sobriety, regular psychotherapy, and AA meetings have been very effective in controlling her anxiety and panic. Her greatest fear is being separated from her children who she loves dearly, and is the primary caregiver for. Given their high needs it is very concerning how they would effectively cope given her absence, and dramatic change in structure.

Sincerely,



Kelly Theodore PMHNP-BC, FNP-BC

Judge didn't
read prior to
sentencing (if
at all)

13

December 30, 2020

To Whom it May Concern,

I am writing this letter as a character reference for Zach and Katie Bloom. I have worked for the Wisconsin Early Autism Project for 23 years. I have also worked for the county (DHS) as a respite care worker and daily living skills provider for about 20 years.

I have known Zach and Katie for approximately 4 years. I initially met them in a professional capacity. I was assigned to their son Robbie's treatment team as the Clinical Supervisor through Wisconsin Early Autism Project. Zach and Katie were very involved in Robbie's treatment. They always had input and worked with the entire team collaboratively. They were quick to purchase and gather needed materials and implement any behavior plans. I was later placed on their daughter Molly's team when she began services shortly after Robbie. Again, Zach and Katie were very involved in her treatment and followed through on all clinical recommendations made by the team. Zach and Katie have been some of the very best parents I have worked with, their level of involvement and follow through in their children's intensive behavioral therapy is top notch.

Robbie has moderate to severe autism and requires constant supervision. He has made many attempts to leave his home as he is unaware of danger. He is non-verbal and cannot communicate his needs and wants expressively. Katie and Zach have learned to read his non-verbal signals and respond to his unique non-verbal communication to meet his needs and wants. He will likely need support throughout his life span.

After Zach and Katie changed to In Bloom for their ABA provider, I maintained a relationship with their family as a respite provider and friend. I spent some weekends providing respite care for their children. They left extensive notes describing medications and routines for the children that were very helpful. They always provided plenty of supplies for their care and were easy to reach by phone for any questions. One thing that stood out to me during respite care was that when Zach and Katie would come home from their time away, they would immediately set their bags down on the floor and go right to their children and give them their undivided attention.

As a friend I have been in their home many times and observed them parenting and interacting with their children. Their abilities to care for and parent two children with special needs is nothing short of amazing. They both have incredible levels of patience and take care of their children's emotional and physical needs. I have brought my own children to their home and have left (two of whom have disabilities) them in their care without any concerns.

During both my professional and social visits to the family home I have never seen any evidence at all of drug use. I did not see any impairments in judgement or behavior at all. Never once did I feel the children were at any kind of risk while in the care of their parents.

Thank you for your time. I would be happy to provide further information via email or phone call.

Sincerely,



Sarah Parker

262-689-3122

Sarah.parker@wiautism.com

14

M. Thea Showstack
29 Buena Vista Way
Hanover, Ma 02339

March 30, 2021

Re: Catherine Dean Bloom

Judge didn't
read prior to
sentencing (if
at all)

To Whom It May Concern:

I am writing in reference to Catherine ("Katie") Dean Bloom, a dear friend of mine for over thirty-six years. Katie and I grew up together and our families have always been close. Katie has consistently been a kind, selfless, and loyal friend. Growing up, she was a responsible student and a talented musician.

As we grew up and had families of our own, Katie and I remained connected and saw each other regularly, despite living far apart. It has been my honor to watch Katie become a wonderful mother. I have seen firsthand on multiple occasions the kind of dedication, patience, and focus that Katie brings to motherhood. Our families vacationed together in the summer of 2019, and it was inspiring to see Katie selflessly caring for her two young children.

Katie's children, Molly and Robbie, are so joyous and curious. They also have complex special needs and have diagnoses on the autism spectrum. Katie and her husband, Zach, have advocated tirelessly for their needs at school and in the community. Without a second thought, they have adapted their home to give Molly and Robbie extra sensory and therapeutic opportunities. Katie has seamlessly managed a team of therapists and care workers and has consistently demonstrated that her children come first.

In my career as a School Psychologist, I have worked with many families with children who have special needs. I've observed that Katie is both extremely competent and open to the advice of the specialists working with her children. In my professional opinion, consistency is of paramount importance to children with special needs, particularly those with autism spectrum disorder. Katie has always been her children's primary caregiver, anticipating their needs and helping them work toward meeting goals and acquiring new skills. When she has had to be away from her children for any length of time, it has had a devastating impact on both children, particularly Robbie. I humbly ask that you make this a primary focus of consideration in reaching your decisions pertaining to Katie's case.

Please do not hesitate to contact me if I can provide greater clarity.

Sincerely,

M. Thea Showstack

M. Thea Showstack, M.Ed., Ed.S.
Nationally Certified School Psychologist
(617) 359-0098
Theashowstack@hotmail.com

Special Needs Child Alert

updated June 2020

**Robert (Robbie) Bloom**

age: 5 years old (DOB Nov 2014)

weight: 42 lbs

height: 44 inches

light brown hair & green eyes

address: W73N397 Greystone Dr

MOM: Katie Bloom 414.839.4178

catherinem bloom@gmail.com

DAD: Zach Bloom 414.861.7593

zacharyabloom@gmail.com

distributed throughout
neighborhood 2019 2020

15

Hello Neighbors!

We are Zach & Katie Bloom. We live in Cedar Pointe on Greystone with our children Molly (7) and Robbie (5), both of whom are autistic. Robbie's autism is more severe, he remains mostly non-verbal, struggles with sensory issues and has little safety awareness. This means we need your help to keep him safe. He might wander away from our home and not know he's lost. Although he can hear & often understands you, he rarely responds to his name, verbal commands or questions. Robbie is also dangerously drawn to bodies of water although unable to swim, runs into the street without looking, and is a proficient climber & runner. He might walk into your home or yard if a door or gate is left open, or hide in a crawl space.

Both kids have been making incredible progress with their special education and therapies, but we need to be proactive since Robbie has a history of eloping and can be especially stealthy. We never allow him to play outside of our home or yard unattended - so if you see him wandering without an adult, we are likely frantically looking for him, and ask for your help with this. We also use a special GPS device, jibit, but this is worn on his clothing and can lose battery or fall off.

IF YOU SEE ROBBIE ALONE:

Please stay with him or keep him in your eyesight. Please call Katie/Zach immediately. His favorite things are trampolines, swings, bubbles, animal & helicopter figurines, sticks, music, and special treats like berries, pretzels, m&ms and skittles. He loves to be outside, and is afraid of dogs and loud noises. The best way to get and sustain his attention is by remaining in place and singing any childrens song - Old McDonald, twinkle twinkle little star, and the alphabet are favorites.

THANK YOU SO MUCH!!

both
to CPD
to
meet
w/ past
chief
about
this
in 2019?
He laughed
& told us
a story
about a
boy that
got out
of his
house in
PJ's
in winter
before parents
knew he
was
gone.

How is
this funny
Every
day
I worry
Robbie
could
die
this
way

letter given to Michael Hart 10/16/20 18

30 days into CPS inv. still hadn't contacted ped or ABA.

I was not reunified for over another month

October 16, 2020

Dear Courtney, Anna, Carey and Lisa,

Mary, Eileen, Larry and Zach are writing to you today to provide an update on Molly and Robbie. We are very grateful and appreciative that you have given us the opportunity to nurture and care for both Molly and Robbie as well as help support the family during this difficult time. Every day is a welcome new adventure and we are all working very closely together to insure all of the children's needs are being met with the utmost care. In Robbie's case, we have been coordinating with the school (Westlawn in Cedarburg) and his ABA therapy provider (inBloom) to secure the best possible support and development plan in all of his environments, despite the challenges created as a result of the COVID-19 pandemic. As part of his modified IEP plan with the school, Robbie will start receiving custom tailored goal oriented on demand learning modules that can be accessed with his IPAD. He will also begin attending virtual large group morning meetings with the help of his teacher and an in-home ABA therapist. In Molly's case, we continue to nurture her love of music and art with frequent in home craft projects (including pumpkin painting) and piano and guitar play-a-longs with dad. In addition, we signed Molly up for swim lessons because she loves the water and we want to make sure she has the appropriate skills to be safe and still have fun. We all become very excited and heart filled with Molly's joy, especially when she wants to engage with us in play and games. Lastly, over the previous 3 weeks we have made sure that both Molly and Robbie are up to date with their respective annual medical check-ups and vaccines and have received good, healthy reports on both children from their pediatrician, Dr. Kevin Dahlman.

they were current before arrest 9/17/20

However, despite all of the good things that we think are going on in the home and with their care, we are all starting to witness some adverse behaviors in both Molly and Robbie. For example, Molly has started to express resistance to going to school (where before, school was the highlight of her day). She has also grown very clinging to caregivers and we have come to experience her emotional breakdowns more frequently when a caregiver transition occurs. Her behavior has also become more adversarial and frustrated in the presence of caregivers, which is heartbreaking as a father to witness because she has always been such a happy and wonderfully joyous person. Robbie has taken more frequently to his room by himself when he is not in therapy. It is equally heartbreaking when we interact with him in play and song and he responds by leading us to the door so that he can be by himself. We have also noticed he has reverted back to more regular head banging during the day in order to regulate himself and has even begun to cry "Mamama" when an unwelcomed transition occurs.

RB had emergent dental surgery 1 wk prior

We have discussed our observations at length with each other and are all in agreement that in our opinion, the absence of their mother is starting to have a more real adverse impact on their well-being. In addition, we would all like to help in any way we can to insure both Molly and Robbie are not negatively impacted in this or any regard. We believe that a plan which includes Katie back in the home full time in the near future is ultimately best for the children. If you agree, we are more than willing to adhere to any additional accommodations you deem necessary for a new protective plan that includes Katie in the home because we truly believe it will be in the best interest of Molly and Robbie.

Thank you for your time and consideration,

Mary Gramza Faulds
Eileen Dean
Larry Dean
Zachary Bloom

Emailed to my atty Hart

10/31/20

Honest w/police and CPS intake w/Anna

Dr Dahlman: "hope CPS resolves quickly, kids need to be with you" - provided CPS 9/21

- Seen throughout year w/typed updates of strengths, challenges, current goals

Kayla/ABA BCBA: my "presence vital to Robbie's progress" - provided CPS 9/21

- Full staff of mandated reporters in house 27.5 hrs/week

Carey Gremminger/CPS supervises visits: acknowledges my role as kids' primary caregiver esp w/Robbie's nonverbal status, we "are a machine"

"Clearly very capable, high-functioning parents"

"Sees two kids who need both parents"

"Would be returning soon after Zach"

"Sees no safety concerns and documents every family centered activity we do at each supervised visit"

Acknowledges concerns of damage my prolonged absence is causing them, shared increase of self-injurious behaviors in my absence, headbanging saying "mama," increased aggression during therapy, new behavior of starting to choke himself week of Oct 19th, Molly regular wetting at school, separation anxiety behaviors from caregivers, and extreme mood fluctuations.

Carey "doesn't want what CPS is doing to cause more harm than initial situation" "Initial situation" WAS being ripped from family for something legal in 12 nation

Lisa Dietrich/CPS ongoing caseworker: "very impressed with kids schedules"

"Sees no neglect, they are in every program they should be"

"Doing everything I should be in recovery"

"Wishes she could clone us"

"We are an anomaly"

Recovery: daily AA meetings

Step work with sponsor Tracy Q

Weekly sponsor family meetings via zoom

Ongoing therapy sessions w/Susan Dellutri - seen since 2006

Psych meds from NP Kelly Theodore - onset 10/8/2020, f/u scheduled 11/11/20

Spiritual counseling w/priest Father Kevin McManaman since 2011 and regular mass

ZB alanon and counseling

Oct 19th Atty Michael Hart s/w Rhonda re: urgency moving forward b/c of kids needs, increase of behaviors from stress of prolonged separation; moving forward w/ consent decree. Met with Lisa first time Oct 21, ZB met w/Lisa Oct 23. Lisa and Carey meeting w/their supervisor Oct 30th to discuss next steps

No use of anything besides OTC meds and current prescribed rx since Sept 18th - drug test w/Anna Sept 21, Oct 28 w/Carey

19
- despite feedback coming from within their own dept, did not reunify until late Nov

Knew couldn't act like hysterical mom begging for kids b/c of MJ, legal mess,

mental health past

Very measured + doc everything + Mini's doc

20

Current safety measures in place now:

- 24/7 family supervision by retired special ed teacher, doctor, psychotherapist overseeing Zach's parenting and all home activities
- Full staff of mandated reporters doing therapy 30 hrs/week
- Both kids in school w/IEPs
- Current w/dr and dental appointments, up to date w/vaccinations etc, well followed

Character References:

- Dr Dahlman: ped since birth
- OT Lindsey Johnson: Robs current OT 2020
- ABA Kayla: current BCBA, 3x/week 2020
- ABA Brady, ABA am shifts 2020
- ABA Kaitlyn, ABA aft shifts 2020
- ABA Liz, ABA eve shifts 2020
- Trinn Rigert, prof relationship since 2016-2020 both kids and 2020 summer respite w/Molly two mornings a week when off professional team 2020 aged out
- Sarah Parker, prior lead therapist w/WEAP, personal friend/respite provider 2019-2020
- Cheyenne Mullikin, prior therapist w/WEAP 2017-2018, friend 2019-2020
- Dani Yabuta, next door neighbor 2016-2020
- Kelly/Dan Jones, next door neighbor 2015-2020
- Thea Barnard, friend and school psych in Boston 1984-2020
- Mariah Goecke, friend 2017-2020
- John Kendall for Zach
- Al & Judi Ruppel, Katie's old boss, family friends & active in recovery efforts 2007-2020
- Doug McManus lifetime family friend

21

STATE OF WISCONSIN, CIRCUIT COURT, OZAUKEE COUNTY

IN THE INTEREST OF

OBERT Z. BLOOM

Name

11/21/2014

Date of Birth

**Stipulation for Consent Decree
(In-Home Placement Only)**Case No. 2020JC000021

The parties stipulate and agree that the court may order ☒ a consent decree ☐ an amended consent decree placing the child/juvenile under supervision, consistent with these terms and conditions:

1. ☒ A. The case shall be held open for _____ days/ six (6) months.

[Chapter 48, up to six months; Chapter 938, up to one year.]

- ☐ B. The consent decree shall be amended. The original expiration date is _____.

2. Placement shall be in the child's/juvenile's home.

3. The child/juvenile shall have no referrals to intake and/or violations of federal, state or local laws.

- ☐ 4. Restitution,

\$ _____ [Under age 14, \$250 limit], payable to _____

☐ Payment terms _____

☐ Make repairs or provide services agreeable to the victim. [Under age 14, 40 hour limit]

☐ See attached

- ☐ 5. Community service/supervised work program. [Under age 14, 40 hour limit]

Amount _____ hours Terms _____

- ☐ 6. Counseling. _____

- ☐ 7. Other: [Include payment for services under §§48.36, 938.36, 938.361, Wis. Stats.]

☐ See attached

8. The court may extend this decree for an additional 6 months upon notice and motion. Unless an objection is made, no hearing will be held.

Court appointed GAL named to OZ Co Prosecuting ADA - gross contact of interest

Child/Juvenile

Name Printed or Typed

Address

Email Address

Date

Telephone Number

State Bar No. (if any)

Parent 1

Catherine M. Bloom

Name Printed or Typed

W73 N397 Greystone Drive, Cedarburg, WI 53012

Address

Email Address

Date

Telephone Number

State Bar No. (if any)

Courtney L. Meyer

Child's/Juvenile's Attorney/GAL

Courtney L. Meyer

Name Printed or Typed

P.O. Box 2, Cedarburg, WI 53012

Address

clmeyerlaw@gmail.com

Email Address

11/9/2020

Date

262-421-5248

Telephone Number

1085885

State Bar No. (if any)

Zachary A. Bloom

Parent 2

Zachary A. Bloom

Name Printed or Typed

W73 N397 Greystone Drive, Cedarburg, WI 53012

Address

Email Address

Date

Telephone Number

State Bar No. (if any)

22

Prosecuting Attorney
Rhonda K. Gorden
 Name Printed or Typed
1201 S. Spring Street, Port Washington, WI 53074
 Address
rgorden@co.ozaukee.wi.us 262-284-8300
 Email Address Telephone Number
1024368
 Date State Bar No. (if any)

Case Worker
Lisa Dietrich
 Name Printed or Typed
121 W. Main Street, Port Washington, WI 53074
 Address
ldietrich@co.ozaukee.wi.us 262-284-8200
 Email Address Telephone Number
 Date State Bar No. (if any)

Notice: During the period of this consent decree, the child/juvenile may object to its continuation and the hearing under which the child/juvenile was placed on supervision may be continued as if the consent decree had never been entered.

CONDITIONS FOR CONSENT DECREE

1. Catherine and Zachary Bloom will demonstrate protective capacities by ensuring there are no illegal or dangerous substances in their home. They will refrain from associating with people who are not law-abiding. They will follow bail conditions.
2. Catherine and Zachary Bloom will demonstrate protective capacities by ensuring Molly and Robert's special needs are met. They will ensure current service providers In Bloom (ABA), Rehab Resources and Westlawn Elementary School, continue to have necessary access to the children to address their special needs. Catherine and Zachary will continue to follow recommendations and will use methods learned from service providers with the children to ensure their wellbeing and continued development. In cases of Covid-19, they will be flexible with appointments and will follow Covid-19 restrictions. They will maintain appointments with providers in a safe way.
3. Catherine Bloom will maintain absolute sobriety. Catherine Bloom will attend AA meetings every day. This schedule can be modified at the Department's discretion. She will have a Sponsor and will remain in good standing with her Sponsor.
4. Catherine Bloom will attend individual therapy with Susan Dellutri, LMFT, LCSW, CASC no less than two times a month. She will follow Ms. Dellutri's recommendations.
5. Catherine Bloom will meet consistently with Kelly Theodore, PMHNP at Tulaya Wellness for medication management. She will only take medications that are prescribed to her and she will take them only as they are prescribed. Catherine will follow recommendations made by Ms. Theodore. Catherine will notify the Department of any medication changes.
6. Zachary Bloom will attend Al-Anon no less than three days a week. This schedule can be modified at the Department's discretion. He will have a Sponsor and will remain in good standing with his Sponsor.
7. Zachary Bloom will attend therapy with Tom J. Vanden Heuvel, SAP, LCSW, SAC, CEAP no less than two times a month. He will follow recommendations made by Mr. Vanden Heuvel.
8. Catherine and Zachary Bloom will cooperate with the Department by allowing the Department access to their home when requested, meeting with the Department as requested, signing releases of information, submitting to drug screens requested by providers and the Department, and informing the Department of changes in employment, phone numbers, address and people residing in the home.



DEPARTMENT OF HUMAN SERVICES

Liza Drake, Director

May 18, 2021

Mr. and Mrs. Bloom
W73 N397 Graeystone Drive
Cedarburg, WI 53012

Dear Catherine and Zachary,

I am writing to let you know I have closed your case with the Department. You have successfully met all of the conditions in the Consent Decree filed on November 16, 2020. Both of you have been extremely cooperative and have been a pleasure to work with. I have found the information you have shared with me about different AA and Al-Anon groups to be extremely helpful. Your scheduling and use of therapy and supports has clearly been beneficial to you. I appreciate the efforts you have both made to improve your selves and your relationship. You are strong advocates for your children and have demonstrated parental protective capacities in regard to meeting their special needs and keeping them safe. The safety net you have established with your family to meet your needs and to care for your children is impressive. Keep up the awesome work!

Please feel free to contact me with questions in the future.

Sincerely,

Lisa Dietrich
Lisa Dietrich, MSW, CAPSW
Ongoing Social Worker



Katie Bloom <catherinembloom@gmail.com>

24

for what its worth

2 r ages

Katie Bloom <catherinembloom@gmail.com>

Tue, Dec 22, 2020 at 9:04 AM

To: Lisa Dietrich <ldietrich@co.ozaukee.wi.us>, Carey Gremminger <cgremminger@co.ozaukee.wi.us>, Samantha Asselin <sasselin@co.ozaukee.wi.us>, "Dahlman, Kevin" <Kevin.Dahlman@aah.org>

Good morning,

An article has surfaced online about Robbie's ABA therapist, Brady.

<https://www.washingtoncountyinsider.com/possession-child-porn/>

This article indicates that the Sheriff's Office received their tip on Brady from a credible source (Wisconsin Department of Justice) in early October. This is two months before Brady was arrested and his employer and clients were notified of his activities. It concerns me greatly that the authorities had this information for this length of time while Brady had unsupervised access to our nonverbal son. I understand that an investigation needs to be developed before formal charges are filed. However during our investigation of my pot use which I was using medicinally to juggle the extensive 24/7 kids care needs, I was not allowed in my home and my kids were withheld from their primary caregiver while Robbie slammed his head into the wall and cried out for me every night. Concurrently, while an investigation is being developed on a pedophile, he is continually given unrestricted access to someone in the same victim range with no one watching, and Robbie is completely incapable of reporting inappropriate behavior. As a sexual abuse survivor who was raped by three different people I knew and trusted, it is horrifying to me that the authorities were aware of this and he was continued to be allowed in our home alone with Robbie. Its all said and done now, but I think this issue needs to be addressed in the system somehow to prevent further damage to other innocent children.

Thanks,
Katie Bloom

From: Lisa Dietrich <ldietrich@co.ozaukee.wi.us>
To: Katie Bloom <catherinembloom@gmail.com>

Tue, Dec 22, 2020 at 9:02 AM

Thank you for sharing this.

Lisa Dietrich, MSW, CAPSW

Social Worker II

Ozaukee County Department of Human Services

121 West Main Street

P.O. Box 994

Port Washington, WI 53074

262-284-8233



CONFIDENTIAL NOTICE This electronic mail message and any files transmitted with it are confidential and are intended for the sole use of the individual or entity to whom they are addressed. Dissemination, forwarding, printing, or copying of this electronic mail without the consent of the sender is strictly prohibited. If you are not the intended recipient, be advised that you have received this electronic mail in error; please immediately notify the sender by return mail or telephone.

25



Katie Bloom <catherinembloom@gmail.com>

E investigation 2020

3 messages

Katie Bloom <catherinembloom@gmail.com>

Wed, Sep 27, 2023 at 8:55 AM

To: Ashley Edwards <Ashley.Edwards@washcowisco.gov>

Cc: "Michael F. Hart" <mfhart@hartpowell.com>, cmast@cmrc-law.com, "Rebecca Coffee, M&C Law" <rcoffee@cmrc-law.com>

Good morning, Ashley!

I hope you are well. I was wondering if you would have time to meet with me briefly in the next few weeks, I have a couple questions about the timeline of Brady's investigation and the time he was in our home. We have pretty extensive documentation of concerning behaviors the kids were exhibiting from that timeframe in the home, at therapy, and at school because of the legal charges that were pending for us and I was just wondering if you would have time so I could share it with you. Our lawyers are reviewing it now but that is moreso for the concerns on the Oz Co DHS side but a little clarification from you would be super helpful as we sort this out.

Thank you for your help!!
Katie

Ashley Edwards <Ashley.Edwards@washcowisco.gov>

Thu, Sep 28, 2023 at 8:52 AM

To: Katie Bloom <catherinembloom@gmail.com>

Good Morning Katie!

I hope you are well. I just wanted to let you know that all of the Sheriff's Office reports are available for open records requests. If you would like them you can contact Kim Becker at 262-335-6815; Brady's case # is 20-37838. I have been incredibly busy as I just came back from 2 weeks of training that ended last week and today is my last day before vacation. If there is something specific that I can answer for you I would be happy to do so. Please let me know.

Thanks,
Ashley

**ASHLEY EDWARDS #422****Detective**Email: ashley.edwards@washcowisco.gov

Desk Phone: (262) 335-4407

Fax: (262) 365-6561

Washington County Sheriff's Office

Rof's Ave.

West Bend, WI 53090



@WashcoWisco

DISCOVER. CONNECT. PROSPER.



Katie Bloom <catherinembloom@gmail.com>

Email meeting

3 messages

Katie Bloom <catherinembloom@gmail.com>

Wed, Sep 27, 2023 at 5:04 PM

To: rfitting@cityofcedarburg.wi.gov

Cc: Ashley Edwards <Ashley.Edwards@washcowisco.gov>

Hello Capt Fitting!

Happy third anniversary! j/k Thank you again for your personal kindness and professionalism during our unfavorable meeting in 2020 when I had all that weed in my house and the way I packaged it in single servings for micro dosing my PTSD history made it look like I was Nancy Botwin selling to Cedar Pointe and the PTA. Again, I feel that entire situation was divine intervention because so, so much good has come from it. The kids are happy and thriving. Thank God. Estranged family relationships were repaired, my marriage is strong as a rock. Thank God. My husband is a saint. We found an incredible respite provider who is my right hand and incredibly patient. Every faculty member at Westlawn and their entire medical team are all angels and our children have made incredible strides in the last year, especially. We are incredibly lucky and very grateful for the resources we have. I hope you are well. I have enjoyed completing my sentence and having that chapter of our lives behind us.

I was actually wondering if you would have time for a brief meeting with me. Lisa Dietrich closed our CPS case with a letter of recommendation in May 2021 and I have some questions about the timeline and protocol of the CPS investigation while I was withheld from the kids for 66 days as their primary caregiver. I'm not sure if you were ever made aware of this, but unfortunately at the same time, one of Robbie's ABA therapists, Brady Wycklendt, was being investigated by the Washington County Sheriff's dept on 4 tips from WI DOJ they received in October 2020. He was ultimately arrested early Dec 2020 on 20 counts of child porn and some drug charges. With the recent third anniversary of Zach and my arrests, I was up the other night reviewing documentation from these events in 2020-2021, much of which I haven't thought about since. We have thorough documentation from the family in our home caring for Molly and Robbie in my absence, the school, and the therapists which we sent to CPS and the attorneys about concerning behaviors of trauma both children were exhibiting at that same time frame asking them to expedite our reunification but would not. I do not even think they called their ABA provider, who had mandated reporters in our home for 30 hours a week for essentially the same time my parenting was in question it was supervised. Of additional concern to me, is the fact that the GAL assigned to protect the kids is married to an Ozaukee County ADA/prosecutor which seems to be a gross professional conflict of interest. I do not believe she ever conducted an investigation either. I discussed my concerns with our family attorney Margaret Hickey who referred me the head of DCF, our criminal attorneys, and also my community liaison which appears to be you, is that correct? Zach and I have no bandwidth whatsoever for legal action that's not my angle, I'm just looking for information for my files as we continually teach Molly and Robbie right from wrong, and someday (hopefully when they are much older), will need to explain why mommy is a felon. I would like to be able to answer questions I'm sure they have about why I was gone for so long.

If so, please let me know when you might be available for a meeting. No rush.

I have also cc'ed Washington County Sheriff Ashley Edwards, whom I met at Brady's hearing July 2023 and also after to try to help identify some additional potential victims. She is a GEM of a human being. I emailed her this morning as well because we are also unsure of when it became known that Brady was working with kids, Robbie in particular since he's nonverbal and can't report inappropriate behavior, but also Molly because she is in his victim range.

Thank you so much for your time and help as we try to fill in the gaps for their medical record.

Katie Bloom

City of Cedarburg - Ryan Fitting <rfitting@cityofcedarburg.wi.gov>

Thu, Sep 28, 2023 at 8:53 AM

To: Katie Bloom <catherinembloom@gmail.com>

Katie,

Thank you for the email. I'm glad everyone is back together and thriving!

As for the meeting. I'm a little confused as to what will be discussed. Correct me if I'm wrong, but you think that the caregiver, Brady Wycklendt, potentially victimized your children? It also sounds like you reported this to CPS but because the GAL is married to an ADA an investigation wasn't completed? 27

is is correct, please confirm and we can go from there.

Ryan Fitting

Administrative Captain

Cedarburg Police Department

[W75N444 Wauwatosa Rd](#)

[Cedarburg, WI 53012](#)

262-375-7620-ph

262-375-7624-fax

[Quoted text hidden]

Katie Bloom <catherinembloom@gmail.com>

Thu, Sep 28, 2023 at 4:33 PM

To: City of Cedarburg - Ryan Fitting <rfitting@cityofcedarburg.wi.gov>

Thank you for getting back to me and for your clarifying questions. No, not that, moreso just looking for some sort of personal closure on the issues of how my kids' care and treatment was handled. But I have since talked with my husband again and am realizing that for now, we might not have the energy to go further at this time. I appreciate your willingness to listen, all you have done for my family and I, and how you have handled this.

Thanks again,
Katie

[Quoted text hidden]

28

Washington County man charged with multiple counts of possession of child porn | By Lieutenant Tim Kemps

By Judy Steffes DECEMBER 18, 2020

10717

Robbie's ABA therapist in our home every weekday morning until Dec 2020.

Per his criminal trial, images / files of concern collected May-Sept 2020 while w/ Robbie every morning

December 18, 2020 – Washington Co., WI – Brady J Wycklendt, 33, has 3 hours – been in Washington County Circuit Court with 15 counts of possession of child pornography as well as several drug charges.

Robbie unable to report signs /

Inappropriate behaviors. I was not allowed in home for essentially same time period on pot charges. Robbie + Molly both exhibiting behaviors of trauma very well documented



He was arrested on the morning of December 9th by Washington County Sheriff's investigators after a search warrant was executed at his Town of Polk residence. Numerous electronic devices, a marijuana grow operation and a small number of prescription pills were seized during the raid.

This case originated from a cyber-tip that the Washington County Sheriff's Office received from the Wisconsin Department of Justice in early October. The images in question involved young children being sexually assaulted by adult-aged men.

We do not believe that the victims are known by Wycklendt. Wycklendt told investigators that he had searched for child pornography in the past as a mere investigation into child pornography. He never reported any enforcement.

by home, school + ABA
SEPT 2020 -
SEPT 2021

The Washington County Sheriff's Office Detective Bureau is an active member of the Internet Crimes against Children Task Force. The Internet Crimes against Children Task Force Program (ICAC) helps state and local law enforcement agencies develop an effective response to technology-facilitated child sexual exploitation and Internet crimes against children.

support encompasses forensic and investigative components, training and technical assistance, victim services, prevention, and community education. Washington County Sheriff Martin Schulteis said, "I am appreciative of law enforcement partnerships like this, which allow us to collaborate as a law enforcement community and bring predators like this justice." The investigation revealed Wycklendt works closely with young autistic children as a behavior therapist. This is of major concern for the sheriff's office and the community. The children he worked with can be vulnerable and are in the same age group as the victims in the images that Wycklendt has been charged with. At this time, we have no indication that any of his clients were victimized. We have been working closely with his former employers to inform families that have worked with Wycklendt. Even though formal charges were filed, the investigation remains open.

Wycklendt's bail does not allow him to have any unsupervised contact with minors or internet access. Any former clients of Wycklendt who have information or concerns can contact the Washington County Sheriff's Office Detective Bureau at (262) 335-4846 or email Investigator Ashley Glamann at Ashley.glamann@washcowisco.gov.

Met w/
Det Edwards
@ her rec'd
7/2023 to help
try to identify
add'l victims -
images she
was never
allowed to
show in court
b/c although
horrifying + upsetting
"they
were
not
illegal"

WI : DOJ
rec'd tips on Brady Oct 2020. During his investigation, he was allowed unlimited access to nonverbal son unable to report inappropriate behavior while primary caregiver was withheld from him on weed charges. For almost the same amount of time at the same time. He was not arrested + removed from our home until Dec 2020

- disabled potential victim still given access for almost 2 months
WTF

AA log of internet mtgs during cond - shared w/cps so

Sundays		they could share with other clients/	
As Bill Sees It	6am	Day Openers Group Wallingford, CT	Mtg: 519-010-213 p/w: stay
	8am	Early Risers Grp Madison	Mtg: 592-202-3864 p/w: 986396
	8am	New Day Club Topic	Mtg: 945-643-612 p/w: (aazoomhelp@gmail.com)
	10am	24 Hr Club 134 Serenity Seekers	Mtg: 645-879-121 p/w:
	10am	Milwaukee Gp Open Speaker	Mtg: 897-469-7046 p/w: 0
	11am	Morning After Grp Madison	Mtg: 959-036-223 p/w: 311337
	11am	Renegade Women's Mtg Madison	Mtg: 775-302-5441 449360
	11am	Solution Big Bo	278-1282-059 5151
Open Discussion	12pm	Atlanta	-4656-7484 011
	1pm	Favorite F Fort Myers	601-2832 m
AA Stories & Shares	1:30pm	Spirit of the	772-540-4263 p/w: 123123
Tradition Study	2pm	New Horizons Group	Mtg: 914-633-670 p/w: 164164
	3pm	Not a Glum Lot Grp (open) Madison	Mtg: 510-212-268 p/w: 606042
	3:30pm	Ladies Speaker Mtg Fort Myers	Mtg: 957-0260-6710 p/w: none per app
	4:30pm	Sunday Night Promises Fort Myers	Mtg: 827-7404-8527 p/w: promises
	5:00pm	The Grapevine Group Bloomington, IL	Mtg: 836-0486-5368 p/w: 061035
	5:30pm	By the Book Group Madison	Mtg: 508-237-365 p/w: bythebook
BB pp 170-559	6pm	Beginners Book Study	www.beginnersbookstudymeeing.org
June	7pm	Sunday Night Surrender	Mtg: 596-194-781

P. 1 of 11
shared

parents
who

couldn't
get to
meetings

Rescheduling of Marijuana

1

Docket No. DEA-1362

Drug Enforcement Administration,
Attn: Administrator,
8701 Morrisette Drive, Springfield, VA 22152,

Dear DEA Administrator,

As instructed per Federal Register notice # (DEA-Docket #1362) I am giving the required written notice of my intention to participate, for review by the agency, in the upcoming hearing concerning the rescheduling of marijuana tentatively scheduled for Dec. 2, 2024.

(1) State with particularity the interest of the person in the proceeding;

I wish to be heard at the rescheduling hearing because I bring a unique set of experiences which includes being a former pharmaceutical chemist, a forensic chemist, business owner & DEA-registrant who has been impacted by neighboring marijuana businesses and recognizes the additional impact the marijuana industry has on my location, state, and across the country through my experiences.

(2) State with particularity the objections or issues concerning which the person desires to be heard; and

The marijuana industry has long known that the creation of "CBD and hemp" industries provides a ready supply of bulk CBD which is easily converted into THC without the greater public's knowledge of these facile processes. This lack of awareness has thwarted unwanted attention by members of the public to the marijuana industry.

The drafting of marijuana legislation with expedited timelines and creative loopholes has resulted in governments not being able to finalize regulations within such short time periods thus invoking wording that allows a much longer timeframe before regulations can take effect.

The filing and granting of multiple expedited marijuana processing patents, based on known illicit extraction/recovery procedures, that should not have been eligible for patent protection due to the federally-controlled, illicit nature of Marijuana.

The continuous, indiscriminate advertising of marijuana businesses in a major grocery store chain exposing and enticing minors to visit and "save" on the purchase of marijuana related products.

The blocking of nearby business access from marijuana-related trash dumped on multiple occasions to block another business's front door access. The dumping of marijuana-related trash in a business-park parking lot and the dumping of processed marijuana into another business's dumpster.

Rescheduling of Marijuana

2

Docket No. DEA-1362

Contaminating and abandoning commercial buildings after the cultivation or sale of marijuana and related products leading to run down areas that are hazardous and less appealing to attract legitimate businesses to the area. The death of an attended child through a self-inflicted gunshot wound while one parent, the gun owner, was inside purchasing marijuana and other parent was inside the same vehicle in the dispensary parking lot.

The illicit cultivation of marijuana in three large fields on BLM and national forest land resulting in the contamination of the land with trash and chemicals, illegal logging of the hundreds of trees to make room for the marijuana grows and the resulting deaths, via plane crash, of two investigators following up and looking for additional grow sites in the national forest related to this single marijuana operation. Attempts by the marijuana industry to use "marijuana patients" as expert medical witnesses at trial. The tactic of obtaining affidavits from additional people claimed as "caregivers" to cover the net amount of marijuana seized in medical marijuana cases after the release of the forensic laboratory's case reports.

The storage of bulk marijuana and issues with the evidence deteriorating while in storage adversely affecting eventual scientific examination and causing THC and mold exposure for local agency personnel who are responsible for storing large quantities of marijuana.

The closing and relocation of a United States Post Office due to the continuous odor and contamination from a marijuana business next door.

The creation, due to the interest in marijuana use, of a separation illicit category of drugs, synthetic cannabinoids "spice drugs" and its evolution from 2009 to the rest of the country resulting in hospitalizations, deaths, and impacts on society.

Additional marijuana-industry problems associated with accidental poisonings of minors, the shooting of a minor by a marijuana grower defending their crops, repeated problems associated with stated potency levels on edible products or the lack of warnings on the products that contain THC have resulted in multiple overdoses. Additionally, the regular workplace now has to contend with THC levels in workers and at what level does it constitute impairment? The new associated costs to employers with the added burden such as determining whether someone is fit to work if long-lasting, marijuana related compounds are found in their system and the liability associated with letting people testing positive back to work. These problems all originate from a pseudo-legitimate, state-level marijuana industry whose tactics and problems are expanding to many states. The marijuana industry adversely affects people and society in many ways that are not often initially anticipated. Marijuana and its associated industries are far more reaching and negatively impactful to society compared to the controlled substances found in schedule III.

Rescheduling of Marijuana

3

Docket No. DEA-1362

(3) State briefly the position of the person regarding the objections or issues.

I object to the reclassification of marijuana from a schedule I down to a schedule III controlled substance, including any marijuana-derived products. I am prepared to present evidence to supports the facts stated above and to assist by participating in the hearing.

All notices to be sent pursuant to this appearance should be addressed to:

Tim McKibben
770 Wooten Rd, Unit #101
Colorado Springs, CO.
80915

Respectfully yours,

A handwritten signature in cursive script, appearing to read 'Tim McKibben', written in dark ink.

Tim McKibben

VETERANS INITIATIVE 22

Because We C.A.R.E

Notice of intention to participate for review by the Agency Docket No. DEA-1362

TO: Drug Enforcement Administration, Attn: Administrator
FROM: Shanetha Lewis, Veterans Initiative 22, Executive Director
DATE: 09/29/2024
Docket No. DEA-1362

nprm@dea.gov

Drug Enforcement Administration, Attn: Hearing Clerk/OALJ

Subject: Notice of Appearance

Dear Sir:

Please take notice that _Shanetha Lewis will appear in the matter of: **Docket No. DEA-1362**

(A) (State with particularity the interest of the person in the proceeding.)

My name is Shanetha Marable Lewis, I hold a Master's degree in Medical Cannabis Science and Therapeutics from the University of Maryland School of Pharmacy. I am a proud disabled Army combat veteran, spouse of a 20 year retired disabled Army combat veteran, and I am also the Executive Director of Veterans Initiative 22.

(B) (State with particularity the objections or issues, if any, concerning which the person desires to be heard.)

I am writing to express my strong support for rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act. I am here today representing my organization and to advocate for myself and our heroes at home, we are a population that is adversely affected or aggrieved by this subsequent ruling. We are also a population that overwhelmingly supports medical cannabis and a population that is disproportionately effected by PTSD, Suicide, and Mental Health issues. As a veteran, wife of a veteran, Executive Director of a veteran centric Non-Profit, and an educated cannabis professional I believe this change is crucial, particularly for the well-being of our nation's veterans.

VETERANS INITIATIVE 22

Because We C.A.R.E

(C) (State briefly the position of the person with regard to the particular objections or issues.)

Rescheduling cannabis to Schedule III would:

1. Facilitate much-needed research into cannabis's therapeutic potential, especially for conditions prevalent among veterans such as PTSD, chronic pain, and anxiety disorders.

2. Improve veterans' access to alternative treatment options, potentially reducing reliance on opioids and other medications with severe side effects.

3. Align federal policy more closely with the growing body of scientific evidence supporting cannabis's medical applications and the 38 states that have legalized medical cannabis use.

4. Reduce legal barriers for veterans who choose to use medical cannabis in states where it's legal, eliminating the risk of losing VA benefits.

All notices to be sent pursuant to this appearance should be addressed to:

Shanetha Lewis

info@veteransinitiative22.com (preferred contact method)

Address:

16517 Sylvan Dr.

Bowie, Md 20715

Respectfully yours,

Shanetha Lewis, MS MCST
Veterans Initiative 22
Executive Director
304-322-6384
info@vetransinitiative22.com

VETERANS INITIATIVE 22

Because We C.A.R.E

Official Letter and Position:

Veterans Initiative 22 is a 501(c)(3) non-profit organization that focuses on helping Veterans, Family and First Responders by providing resources, employment opportunities, and continuously advocating for rights and access to affordable cannabis and Veteran rights. VI 22 was named as such after the estimated 22 Veterans who commit suicide daily due to PTSD, and it is our organization's goal to bring national awareness to this tragedy, while also working to improve the lives of Veterans across the country.

Please note our strong **support** for this rescheduling of cannabis from Schedule I to Schedule III For the following reasons:

My name is Shanetha Marable Lewis, I hold a Master's degree in Medical Cannabis Science and Therapeutics from the University of Maryland School of Pharmacy. I am a proud disabled Army combat veteran, spouse of a 20 year retired disabled Army combat veteran, and I am also the Executive Director of Veterans Initiative 22. I am writing to express my strong support for rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act. I am here today representing my organization and to advocate for myself and our heroes at home. We are a population that is adversely affected or aggrieved by this subsequent ruling. We are also a population that overwhelming supports medical cannabis and a population that is disproportionately effected by PTSD, Suicide, and Mental Health issues. As a veteran, wife of a veteran, Executive Director of a veteran centric Non-Profit, and an educated cannabis professional I believe this change is crucial, particularly for the well-being of our nation's veterans.

Researchers found that PTSD sufferers who used cannabis not only saw greater reductions in their PTSD symptoms, but they were 2.57 times more likely to recover from PTSD during the study than those who weren't using cannabis.

The VA estimates roughly 15% of Vietnam veterans currently suffer from PTSD, but as many as 30% have experienced PTSD at some point in their lives. About 12% of Desert Storm veterans experience PTSD, and between 11% to 20% of War on Terror (Operation Iraqi Freedom and Operation Enduring Freedom) veterans suffer from the disorder. 83% percent of veteran households surveyed indicated that they believe the federal government should legalize medical cannabis nationwide, and 82% indicated that they would want to have medical cannabis as a federally-legal treatment option, the survey says. 93% of caregivers and 92% of veteran households support research into the efficacy of medical cannabis for mental and physical conditions.

VETERANS INITIATIVE 22

Because We C.A.R.E

Rescheduling cannabis to Schedule III would:

1. Facilitate much-needed research into cannabis's therapeutic potential, especially for conditions prevalent among veterans such as PTSD, chronic pain, and anxiety disorders.
2. Improve veterans' access to alternative treatment options, potentially reducing reliance on opioids and other medications with severe side effects.
3. Align federal policy more closely with the growing body of scientific evidence supporting cannabis's medical applications and the 38 states that have legalized medical cannabis use.
4. Reduce legal barriers for veterans who choose to use medical cannabis in states where it's legal, eliminating the risk of losing VA benefits.

The federal government has made a promise to every veteran to provide the best care possible. How are our veterans being cared for properly if they must choose between their economic health and their mental and or biological health?

As is evident by the studies aforementioned, many veterans report significant improvements in their quality of life and symptom management with medical cannabis use. Rescheduling would validate their experiences and open doors for more comprehensive studies to optimize treatment protocols. I urge the DEA to consider the mounting scientific evidence, the potential benefits for our veterans, and the changing landscape of public opinion and state laws. Rescheduling cannabis to Schedule III is a necessary step towards a more evidence-based and compassionate approach to drug policy. Thank you for your consideration of this important matter and for your time in reading my testimony and your consideration of the Veterans Initiative 22 organization's official position on rescheduling. Cannabis is medicine and unrestricted affordable access to cannabis improves and saves lives!

Thank You,

Shanetha Lewis, MS MCST
Veterans Initiative 22
Executive Director
304-322-6384
info@vetransinitiative22.com



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Aubree Adams
Director
Every Brain Matters
aubree@everybrainmatters.org

Dear Ms. Aubree Adams,

This is in response to your request for a hearing dated June 13, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:52:11 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Bryn Spejcher, Au.D., CCC-A, F-AAA
217 Edgebrook Drive
Bloomington, IL 60108
BSpejcher12@gmail.com

Dear Mr. Bryn Spejcher,

This is in response to your request for a hearing dated June 17, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:48:49 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Darwin Richardson
Benuvia Operations, LLC
3950 N. Mays St.
Round Rock, TX 78665
Drichardson@benuvia.com

Dear Mr. Darwin Richardson,

This is in response to your request for a hearing dated June 13, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:47:54 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

David B. Rausch
Tennessee Bureau of Investigation
901 R.S. Gass Boulevard
Nashville, TN 37216

Dear Mr. David B. Rausch,

This is in response to your request for a hearing dated June 19, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:47:03 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Drug Enforcement Association of Federal Narcotics Agents
Marshall Fisher, President
marshallfisher@rocketmail.com
P.O.Box 2801
Ashburn, VA 20146

Dear Mr. Marshall Fisher,

This is in response to your request for a hearing dated June 18, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:42:30 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Heidi Anderson-Swan
736 Gould Ave #6
Hermosa Beach, CA 90254

Dear Ms. Heidi Anderson-Swan,

This is in response to your request for a hearing dated June 15, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:56:26 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Khursid Khoja
c/o Greenbridge Corporate Counsel, P.C.
500 Capitol Mall, Suite 2350
Sacramento, CA 95814

Dear Mr. Khursid Khoja,

This is in response to your request for a hearing dated June 4, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:41:13 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Lori Robinson, M.S., R.D.
Moms Strong
638 Lindero Canyon Rd, #403
Oak Park, CA 91377

Dear Ms. Lori Robinson,

This is in response to your request for a hearing dated June 20, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:36:45 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Michael Rountree, CPA, MBT
300 S. El Camino Real, Suite 206
San Clemente, CA 92672

Dear Mr. Michael Rountree,

This is in response to your request for a hearing dated June 22, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:38:14 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Minority Cannabis Business Association
ATTN: Mike Lomuto
1300 I St, NW, Ste 400 E.
Washington, D.C. 20005

Dear Mr. Mike Lomuto,

This is in response to your request for a hearing dated June 19, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:39:14 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Phillip Drum, PharmD
789 Condor Drive
Martinez, CA 94553
phillipdrum@comcast.net

Dear Mr. Phillip Drum,

This is in response to your request for a hearing dated June 19, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
15:37:30 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Igor Grant, M.D.
Center for Medical Cannabis Research
220 Dickerson Street, Suite B
San Diego, CA 92103

Dear Dr. Igor Grant,

This is in response to your request for a hearing dated July 19, 2024, to the Drug Enforcement Administration (DEA) on the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024).

To determine whether you are an “interested person,” as that term is defined in DEA’s regulations, DEA is requesting that you provide additional information establishing that you are a “person adversely affected or aggrieved by” the proposed rule. 21 CFR 1300.01(b). Further, because the purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances, *see* 21 CFR 1308.42, DEA is also requesting that you provide additional information describing the relevant evidence on a material issue of fact you intend to present during the hearing.

To ensure proper handling of your response, please reference “Docket No. DEA–1362” on all correspondence, including any attachments. Any electronic response should be sent to nprm@dea.gov. Any paper response sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. Any response must be received or postmarked on or before September 30, 2024.

Sincerely,

**MATTHEW
STRAIT**

Digitally signed by
MATTHEW STRAIT
Date: 2024.09.10
16:00:36 -04'00'

Matthew Strait
Deputy Assistant Administrator
Diversion Control Division



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

American Academy of Hospice and Palliative Medicine
Chad Kollas
8735 W Higgins Road, Suite 300,
Chicago, IL 60631

Dear Mr. Kollas,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

American Academy of Hospice and Palliative Medicine
Chad Kollas
8735 W Higgins Road, Suite 300,
Chicago, IL 60631

Dear Mr. Kollas,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', with a long horizontal flourish extending to the right.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Saint Michael's College
Ari Kirshenbaum
409 Colby Hill, Lincoln,
Vermont, 05443

Dear Mr. Kirshenbaum,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", is written over a circular stamp that contains the DEA logo.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Aubree Adams
19011 N. Elizabeth Street,
Pueblo, CO 81003

Dear Ms. Adams,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', with a long horizontal flourish extending to the right.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

BayMedica, LLC
Khurshid Khoja
500 Capitol Mall, Suite 2350,
Sacramento, CA 95814

Dear Mr. Khoja,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also* *Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Dr. Bryn Spejcher
217 Edgebrook Dr.
Bloomington, IL 60108

Dear Dr. Spejcher,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also* *Placement of Lorazepam Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Cannabis Industry Victims Educating Litigators
David Evans
1854 Henersonville Rd., Ste 205,
Asheville, NC 28803

Dear Mr. Evans,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", is written over a circular stamp or seal.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Cannabis Law PA
Attn: Judith Cassel
501 Corporate Circle, Suite 302
Harrisburg, PA 17110

Dear Ms. Cassel,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also* *Placement of Lorazepam Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Cannabis Law PA
Attn: Micah Bucy
501 Corporate Circle, Suite 302
Harrisburg, PA 17110

Dear Mr. Bucy,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Community Anti-Drug Coalitions of America
Sue Thau
500 Montgomery Street, Suite 400,
Alexandria, VA 22314

Dear Ms. Thau,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Hemp for Victory
Dr. Corey Burchman
2061 Le Mans Dr.,
Carrollton, Texas 75006

Dear Dr. Burchman,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', with a long horizontal flourish extending to the right.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Curio Wellness
Edward Rudnic
740 15th Street NW, 5th floor,
Washington, DC 20005

Dear Mr. Rudnic,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also* *Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Hemp for Victory
Dr. Darinia Douchi
2061 Le Mans Dr.,
Carrollton, Texas 75006

Dear Dr. Douchi,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Drug Enforcement Association of Federal Narcotics Agents (DEAFNA)
P.O. Box 2801
Ashburn, VA 20146

Dear Sir/Ma'am,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', with a long horizontal flourish extending to the right.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Massachusetts Cannabis Advisory Board
Ellen Brown
48 Sconset Circle,
Sandwich, MA 02563

Dear Ms. Brown,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Cannabis Ombudsman, State of Connecticut
Erin Gorman Kirk
747 Old Stamford RD,
New Canaan, CT 06840

Dear Ms. Gorman Kirk,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Full Spectrum Inc
Gregory Davenport
176 S. Alvarado Street,
Los Angeles, CA 90057

Dear Mr. Davenport,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Heidi Anderson-Swan
736 Gould Ave #6,
Hermosa Beach, CA 90254

Dear Ms. Anderson-Swan,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

International Academy on the Science and Impact of Cannabis
Roneet Lev
P.O. Box 4187
Burlington, VT 05406-4187

Dear Ms. Lev,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', with a long horizontal flourish extending to the right.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

International Association of Chiefs of Police
44 Canal Center, Suite 200,
Alexandria, VA 22314

Dear Sir/Ma'am,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to be "Anne Milgram", written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Jahan Marcu
347 8th St., Apt 1,
Jersey City, NJ 07302

Dear Mr. Marcu,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

The Doc App. Dba, My Florida Green
Jason Castro
4055 1st Ave SW,
Naples, FL 34119

Dear Mr. Castro,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Jeffrey Fatz
9595 Six Pines Drive, STE 8210,
The Woodlands, TX 77380-1586

Dear Mr. Fatz,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Cannabis Bioscience International Holdings
John Jones
6201 Bonhomme Rd, Suite 466-S
Houston, TX 77036

Dear Mr. Jones,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Kenneth Finn, MD
6025 Delmonico Drive,
Colorado Springs, CO 80919

Dear Mr. Finn,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', with a long horizontal flourish extending to the right.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

American College of Occupational and Environmental Medicine
Natalie Hartenbaum
25 Northwest Point Blvd., Suite 700,
Elk Grove Village, IL 60007-1030

Dear Ms. Hartenbaum,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

National Cannabis Industry Association
Aaron Smith
3845 Tennyson Street, Suite 170,
Denver, CO 80212

Dear Mr. Smith,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

National Cannabis Industry Association
Michelle Rutter Friberg
3845 Tennyson Street, Suite 170,
Denver, CO 80212

Dear Ms. Rutter Friberg,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

National Drug and Alcohol Screening Association
Jo McGuire
1629 K. Street NW, Suite 300,
Washington, DC 20006

Dear Ms. McGuire,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

National Sheriff's Association
1450 Duke Street,
Alexandria, Virginia, 22314

Dear Sir/Ma'am,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", is written over a circular stamp that contains the DEA seal.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

National Transportation Safety Board
Jennifer Homendry
490 L'Enfant Plaza SW,
Washington, DC 20594

Dear Ms. Homendry,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', with a long horizontal flourish extending to the right.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Pharmacists' Cannabis Coalition of California
Jill Simonian
5034 Caminito Vista Lujo,
San Diego, CA 92130

Dear Ms. Simonian,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also* *Placement of Lorazepam Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Phil Molloy
347 8th St., Apt 1,
Jersey City, NJ 07302

Dear Mr. Molloy,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Phillip Drum
789 Condor Drive,
Martinez, CA 94553

Dear Mr. Drum,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Prince Lobel Strategic Advisors LLC
Ronald Lipof
10401 N 100th Street, #5,
Scottsdale, AZ

Dear Mr. Lipof,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also* *Placement of Lorcasein Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Hemp for Victory
Robert Head
2061 Le Mans Dr.,
Carrollton, Texas 75006

Dear Mr. Head,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Sandra Rapke

Dear Ms. Rapke,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Veterans Initiative 22
Shanetha Lewis
16517 Sylvan Dr.,
Bowie, Md 20715

Dear Ms. Lewis,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Smart Approaches to Marijuana
Patrick Philbin
1155 F. Street NW, Suite 750,
Washington, DC 2004

Dear Mr. Philbin,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

State of Nebraska
Attorney General Mike Hilgers
2115 State Capitol,
Lincoln, NE 68509

Dear AG Hilgers,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024


Synthcon LLC
Tim McKibben
770 Wooten Rd., Unit 101,
Colorado Springs, CO 80915

Dear Mr. McKibben,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also* *Placement of Lorazepam Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Tennessee Bureau of Investigation
6040 Century Oaks Drive,
Chattanooga, TN 37416

Dear Sir/Ma'am,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Teresa Simon
347 8th St., Apt 1,
Jersey City, NJ 07302

Dear Ms. Simon,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also Placement of Lorcasein Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

The Commonwealth Project
Katy Green
800 Maine Avenue, SW, Suite 200,
Washington, DC 20024

Dear Ms. Green,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

The Doc App. DBA, My Florida Green
Nicholas Garulay
4055 1st Ave SW,
Naples, FL 34119

Dear Mr. Garulay,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Hemp for Victory
Victor Bohm
2061 Le Mans Dr.,
Carrollton, Texas 75006

Dear Mr. Bohm,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read 'Anne Milgram', written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Village Farms International Inc.
Shane Pennington
2020 K. Street, NW, Suite 600,
Washington, D.C. 20006

Dear Mr. Pennington,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024). Upon review, DEA grants your request.

The hearing is currently scheduled to commence on December 2, 2024, at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, VA 22202. The hearing will be conducted pursuant to the provisions of 5 U.S.C. 556 and 557, and 21 CFR 1308.41-1308.45, and 1316.41-1316.68. Further information regarding the hearing and your participation will be provided by the Administrative Law Judge designated to preside over the hearing.

Sincerely,

A handwritten signature in black ink, appearing to read "Anne Milgram", written over a circular stamp.

Anne Milgram
Administrator



U.S. Department of Justice
Drug Enforcement Administration

Office of the Administrator

Springfield, VA 22152

October 28, 2024

Wei He
2002 Kestral Circle,
Audubon, PA 19403

Dear Wei He,

This is in response to your request to the Drug Enforcement Administration for a hearing or to participate regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. *See Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. *See* 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; *see also Placement of Lorcaserin Into Schedule VI*, 78 FR 26701 (May 8, 2013); *Placement of Lacosamide Into Schedule V*, 74 FR 23789 (May 21, 2009); *Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III*, 64 FR 35928 (July 2, 1999); *Placement of Pemoline in Schedule IV*, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

However, the materials (including any comments) you have submitted will be offered as evidence at the hearing as provided for in the NPRM.

Sincerely,

Anne Milgram
Administrator



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrissette Drive
Springfield, Virginia 22152

www.dea.gov

American Psychological Association
750 First Street NE
Washington, DC 20002
knjones@apa.org

Dear American Psychological Association,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:15:42 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

American Trade Association for Cannabis and Hemp
1900 Sixteenth Street
Suite 1400
Denver, Colorado 80202
AKline@perkinscoie.com

Dear American Trade Association for Cannabis and Hemp,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:16:47 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Americans for Safe Access Foundation
1629 K Street NW
Suite 300
Washington, DC, 20006
steph@safeaccessnow.org

Dear Americans for Safe Access Foundation,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:17:55 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Andrew DeAngelo
andrew@andrewdeangelo.com

Dear Andrew DeAngelo,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
14:19:31 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Andrew Kline
Green Thumb Industries Inc.
1900 Sixteenth Street
Suite 1400
Denver, Colorado 80202
AKline@perkinscoie.com

Dear Andrew Kline,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:20:48 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Ariana Fleishman
ariana.fleishman@gmail.com

Dear Ariana Fleishman,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
14:22:03 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Association of American Railroads
425 Third Street SW
Washington, DC 20024
Sgordon@aar.org

Dear Association of American Railroads,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:23:07 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Association of State Criminal Investigative Agencies
7700 Midlothian Turnpike
North Chesterfield, VA 23235

Dear Association of State Criminal Investigative Agencies,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
14:24:13 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

August Wakat
P.O. Box 700202
Tulsa, OK 74170
august@poeboyssalvage.com

Dear August Wakat,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:25:21 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Brian Austin
1955 Upton Talley Road
Upton, KY 42784
brianraustin@icloud.com

Dear Brian Austin,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:32:09 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Bryan Krumm
733 Monroe St. NE
Albuquerque, NM 87110
reeferdoc@hotmail.com

Dear Bryan Krumm,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:29:21 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Bryon Adinoff
812 S Gaylord St.
Denver, CO 80209
mzorn@yettercoleman.com
adinoff@d4dpr.org

Dear Bryon Adinoff,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:30:07 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Catherine Bloom
W73N397 Greystone Dr.
Cedarburg, WI 53012
catherinembloom@gmail.com

Dear Catherine Bloom,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:28:34 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Coalition for Patients Rights
P.O. Box 868
Clackamas, OR 97015
Jason.Greninger@MyCPR.US

Dear Coalition for Patients Rights,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
14:39:28 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Con Body
121 Ludlow Street
New York, NY 10002
coss@conbud.com

Dear Con Body,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:38:35 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Cris Ericson
crisericson7@gmail.com

Dear Cris Ericson,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:36:01 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Cynthia Mateo
cynthiamateo2241@gmail.com

Dear Cynthia Mateo,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**  Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
14:37:46 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Daniel Kyle
401 SE 18th Ave.
Ontario, OR 97914
fierychrism@gmail.com
Dear Daniel Kyle,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
14:36:58 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

David Heldreth Jr.
14321 Se 49th St.
Bellevue, WA 98006
dheldrethjr@gmail.com

Dear David Heldreth Jr.,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
14:48:51 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Dennis Schuller
admin@legalmarijuanawmn.org

Dear Dennis Schuller,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:49:37 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Derek J Shirley
24 Cambell Shore Rd.
Gray, Maine 04039
gettinghighwithcats@gmail.com

Dear Derek J Shirley,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:48:05 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Devan Maurice Dupuis
62 Washington Street A10
Haverhill, MA 01832
devandupuis@gmail.com

Dear Devan Maurice Dupuis,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:46:20 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Dominique Mendiola
1697 Cole Boulevard
Suite 200
Lakewood, CO 80401
dominique.mendiola@state.co.us

Dear Dominique Mendiola,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:45:37 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Drug Policy Alliance
1796 Bar Harbor Rd.
Columbus, OH 43219
cpacker@drugpolicy.org

Dear Drug Policy Alliance,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:53:48 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Ean Seeb
200 East Colfax Avenue
Room 136
Denver, CO 80203
ean.seeb@state.co.us

Dear Ean Seeb,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:51:31 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Ed Wood
7133 West Arlington Way
Littleton, CO 80123
edwood27@icloud.com

Dear Ed Wood,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
14:53:01 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Emily Fisher
9100 South Dadeland Ave.
Suite 1701
Miami, Florida 33156
zlevin@leafwell.com

Dear Leafwell,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
14:52:16 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Grayson Lichtenthaler
graysonlichtenthaler@gmail.com

Dear Grayson Lichtenthaler,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**
K

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:05:14 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Greenspoon Marder, LLP
1144 15th St., Suite 2700
Denver, CO 80218
Nick.Richards@gmlaw.com

Dear Greenspoon Marder, LLP,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:03:37 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Ian Patrick Patriarca
irpmarketing0805@gmail.com

Dear Ian Patrick Patriarca,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:02:13 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Jasmine Montoya
7893 Wyandot St.
Denver, CO 80221
jasmontoya21@gmail.com

Dear Jasmine Montoya,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
15:01:29 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Jessica Garza
jes.garza20@gmail.com

Dear Jessica Garza,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:11:13 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Jonathan Frank
jonathanfrank84@icloud.com

Dear Jonathan Frank,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:13:43 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Jordan Christopher Zito
zito.jordan@yahoo.com

Dear Jordan Christopher Zito,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:08:17 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Jordan Smith
jordan_rocksmith@yahoo.com

Dear Jordan Smith,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:07:34 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Joseph Garofalo
31 Dartmouth St.
Keene, NH 03249

Dear Joseph Garofalo,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:10:24 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Joshua Taylor
graysonlichtenthaler@gmail.com

Dear Joshua Taylor,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:18:29 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Julie Monteriro
P.O Box 868
Clackamas, OR 97015
julie@compassion-center.org;
james@compassion-center.org;
admin@compassion-center.org

Dear Julie Monteriro,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
15:22:17 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Justin J. Taylor
vwjustin@gmail.com

Dear Justin J. Taylor,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:17:45 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Kai Hoffman
610 Burley Road
Annapolis, MD 21409
kaihoffman@verizon.net

Dear Kai Hoffman,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
15:19:10 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Kainan Boring
kainanmatthew@icloud.com

Dear Kainan Boring,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
15:20:07 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Keila E. Castillo
P.O. Box 9120
Chelsea, MA 02150
keila91castillo@gmail.com

Dear Keila E. Castillo,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:29:26 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Keith G. Freeman
759 Blossom Hill Road
Los Gatos, CA 95032
Keithfree10@gmail.com

Dear Keith G. Freeman,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:28:41 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Kym Silva
kymsilva31@gmail.com

Dear Kym Silva,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:27:56 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Last Prisoner Project
149 Walden St.
West Hartford, CT 06107
sarah@lastprisonerproject.org

Dear Last Prisoner Project,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:27:12 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Lilly Tirado
lillycti10@gmail.com

Dear Lilly Tirado,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcasein Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:49:53 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Lori Robinson
638 Lindero Canyon Rd.
Suite 403
Oak Park, CA 91377
momsstronginfo@gmail.com

Dear Lori Robinson,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK** Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
15:49:07 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Major Cities Chiefs Association
P.O. Box 71690
Salt Lake City, UT 84171

Dear Major Cities Chiefs Association,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:44:18 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Major County Sheriffs of America
P.O. Box 81762,
Rochester, MI 48308

Dear Major County Sheriffs of America,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:46:21 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Mariah Ashley Magnuson
mariah.magnuson@gmail.com

Dear Mariah Ashley Magnuson,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:47:12 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Marijuana Policy Project
2370 Champlain NW
Suite 12
Washington, DC. 20009
kokeefe@mpp.org

Dear Marijuana Policy Project,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaseerin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:55:26 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Michael Doyle
12619 Dunks Ferry Road
Philadelphia, PA 19154
michaeldoylejr@comast.net

Dear Michael Doyle,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:54:41 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Michael Krawitz
1110 Mary Bett Hollow Road
Ferrum, Virginia 24088
miguet@infionline.net

Dear Michael Krawitz,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:51:51 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Michael Rountree
300 S. El Camino Real
Suite 206
San Clemente, CA 92672
mrountree@routtreeconsulting.com

Dear Michael Rountree,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**  Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
15:52:52 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Minorities for Medical Marijuana, Inc.
927 Goldwyn Avenue
Suite 124
Orlando, Florida 32805
eric@m4mmunited.org

Dear Medical Marijuana, Inc.,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:53:52 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Minority Cannabis Business Association
1300 I Street, NW
Suite 400 E
Washington, DC 20005

Dear Minority Cannabis Business Association,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:08:44 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

National Alliance of State Drug Enforcement Agencies
P.O. Box 16278
Austin, TX 78761

Dear National Alliance of State Drug Enforcement Agencies,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:07:19 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

National Association of Police Organizations
317 S. Patrick Street
Alexandria, VA 22314

Dear National Association of Police Organizations,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:00:23 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

National District Attorneys Association
1400 Crystal Drive
Suite 330
Arlington, VA 22202

Dear National District Attorneys Association,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:06:23 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

National HIDTA Directors Association
1800 Washington Blvd.
Suite 150
Baltimore, MD 21230

Dear National HIDTA Directors Association,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:02:16 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

National Narcotic Officers' Associations' Coalition
455 Massachusetts Ave. NW
Box 112
Washington, DC 20001

Dear National Narcotic Officers' Associations' Coalition,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:16:55 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Law Offices of Joseph A. Bondy
NORML
1776 Broadway
Suite 2000
New York, NY 10019
jab@josephabondy.com;
paul@norml.org;
WhitneyEconomics@gmail.com

Dear Law Offices of Joseph A. Bondy,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

THOMAS
PREVOZNIK
K

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:26:21 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

New York State Office of Cannabis Management
1220 Washington Avenue
Building 9
Albany, New York 12226
Felicia.Reid@ocm.ny.gov

Dear New York State Office of Cannabis Management,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcasein Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:17:38 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Nicholas Barreto
400 W. South Boulder Rd.
Suite 17
Louisville, CO 80027
nbarreto89@aim.com

Dear Nicholas Barreto,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcasein Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:16:06 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Nicole Ricci
728 Broadway
Kingston, NY 12401

Dear Nicole Ricci,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:15:01 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Patrick Oglesby
1830 North Lakeshore Drive,
Chapel Hill, NC 27514
po@newrevenue.org

Dear Patrick Oglesby,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
16:12:42 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Perkins Coie
1201 Third Avenue
Suite 4900
Seattle, Washington 98101
AKallon@perkinscoie.com
TTobin@perkinscoie.com

Dear Perkins Coie,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:27:59 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Perkins Coie on behalf of Green Thumb Industries Inc.
700 Thirteenth Street NW
Suite 800
Washington, DC 20005
Bcohen@perkinscoie.com

Dear Perkins Coie on behalf of Green Thumb Industries Inc.,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:27:16 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Perkins Coie on behalf of MedPharm
1201 Third Avenue
Suite 4900
Seattle, Washington 98101
AKallon@perkinscoie.com
TTobin@perkinscoie.com

Dear Perkins Coie on behalf of MedPharm,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:26:19 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Perkins Coie on behalf of MedPharm
2020 K Street NW
Suite 600
Washington, DC 20006
SPennington@porterwright.com

Dear Perkins Coie on behalf of MedPharm,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:25:25 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Perkins Coie on behalf of MedPharm
1900 Sixteenth Street
Suite 1400
Denver, Colorado 80202
AKline@perkinscoie.com

Dear Perkins Coie on behalf of MedPharm,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:24:24 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Rafael Acevedo
bookingruleyalabel@gmail.com

Dear Rafael Acevedo,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
16:32:15 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

RTI International
3040 East Cornwallis Road
P.O. Box 12194
Research Triangle Park, NC 27709
janeallen@rti.org

Dear RTI International,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcasein Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
16:33:04 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Russell Palmer
russ@russellpalmer.biz

Dear Russell Palmer,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:31:09 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Sage Endoom Cannablisshum
1304 Wilkshire Circle SW
North Canton, OH 44720
Sagesamoreorganics@gmail.com

Dear Sage Endoom Cannablisshum,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:29:43 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

San Diego County
kellyjaninethequeen@gmail.com

Dear San Diego County,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:30:24 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Sensible Drug Policy
1800 M St NW, Suite 33051
Washington, DC 20036
kat@ssdp.org

Dear Sensible Drug Policy,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:39:42 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Sergeants Benevolent Association
57 Leonard Street
New York, NY 10013

Dear Sergeants Benevolent Association,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:44:17 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Shane Gallichio
shanildo44@gmail.com

Dear Shane Gallichio,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcasein Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:43:27 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Shane Pennington
2020 K Street NW
Suite 600
Washington, DC 20006
SPennington@porterwright.com

Dear Shane Pennington,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
16:42:44 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Governor Jared Polis
200 East Colfax Avenue
Room 136
Denver, CO 80203
governorpolis@state.co.us

Dear Governor Jared Polis,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
15:04:27 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Stephen J. Mandile
27 Henry Street
Uxbridge, Massachusetts 01569
sjmandile@gmail.com

Dear Stephen J. Mandile,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:40:38 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Students for Sensible Drug Policy
600 17th Street
Suite 2800 South
Denver, CO 802020

Dear Students for Sensible Drug Policy,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaseerin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:49:54 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Dr. Suzanne Sisley
12622 N. 81st St.
Scottsdale, AZ 85260
ssisleymd@gmail.com

Dear Dr. Suzanne Sisley,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**
K

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
14:54:40 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

T. Christopher Wright
2114 E 35th St,
Minneapolis, MN 55407
tc_wright38@yahoo.com

Dear T. Christopher Wright,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:46:48 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

The Equity Trade Network
2261 Market St.
Suite 4
San Francisco, CA 94114

Dear The Equity Trade Network,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**
K

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
16:49:11 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

The Plant Counsel
2609 Leslie Dr. NE
Atlanta, GA 30345
JimFricke@JimFricke.com

Dear The Plant Counsel,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:48:28 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

The Veterans Action Council
veteransactioncouncil@gmail.com
cannabisamericana420@gmail.com

Dear The Veterans Action Council,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:47:42 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Thomas J. Tobin
1201 Third Avenue
Suite 4900
Seattle, Washington 98101
TTobin@perkinscoie.com

Dear Thomas J. Tobin,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
17:07:54 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Training Marbles, Inc.
dmcdowell@trainingmarbles.com

Dear Training Marbles, Inc.,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
17:05:16 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

United Empowerment Party
639 Russell Ave.
Suite 101
Meadville, PA 16335
sephida@unitedempowermentparty.org

Dear United Empowerment Party,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcasein Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
16:57:48 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

United States Cannabis Coalition
P.O. Box 329
Marietta, OK 73448
usacannabiscoalition@gmail.com

Dear United States Cannabis Coalition,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an "interested person" under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
17:01:48 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Veterans Action Council
soijana@proton.me
esaiaagonzalez@gmail.com

Dear Veterans Action Council,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**
K

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
17:16:30 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Veterans Action Council
1700 Chattuck Ave.
Apt 207
Berkeley, CA 94709
atn420@gmail.com

Dear Veterans Action Council,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaseerin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
17:15:46 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Veterans Action Council
soijana@proton.me
esaiaagonzalez@gmail.com

Dear Veterans Action Council,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**
K

Digitally signed by
THOMAS PREVOZNIK
Date: 2024.11.25
17:16:30 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Vicente LLP on behalf of Sensible Colorado
800 Boylston Street
26th Floor
Boston, MA 02199
T.Swain@VicenteLLP.com

Dear Vicente LLP on behalf of Sensible Colorado,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK
K**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
17:12:34 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Vicente LLP
800 Boylston Street
26th Floor
Boston, MA 02199
T.Swain@VicenteLLP.com

Dear Vicente LLP,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcaserin Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

**THOMAS
PREVOZNIK**

Digitally signed by
THOMAS
PREVOZNIK
Date: 2024.11.25
17:13:38 -05'00'

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division

From: [Achbach, Heather E.](#)
To: [Hamilton, Kerry R.](#)
Cc: [Kellstrom, Melissa A.](#); [Washington, Crystal L.](#); [Van Linn, Michael L.](#); [Willenbring, Daniel](#); [Mason, Teneille W](#)
Subject: RE: MJ letters with formatting errors
Date: Wednesday, November 27, 2024 2:38:36 PM
Attachments: [Andrew Kline Marijuana Rejection letters 11252024-.pdf](#)
[Perkins Coie Marijuana Rejection letters 11252024.pdf](#)
[Shane Pennington Marijuana Rejection letters 11252024.pdf](#)
[Thomas J. Tobin Marijuana Rejection letters 11252024.pdf](#)
[Perkins Coie on behalf of MedPharm Marijuana Rejection letters 11252024-70.pdf](#)
[Perkins Coie on behalf of MedPharm 2 Marijuana Rejection letters 11252024-.pdf](#)

And as the last follow up on this before I go make pie crusts and dinner rolls for tomorrow.....

This attached group of letters were not sent out as they were duplicates. We had multiple attorneys included on incoming requests and individual letters were drafted to each attorney. Since the letters were not addressed to the individuals but to the organizations we cc'd the multiple attorneys from each request and sent the single letters so that duplicates were not sent en-masse.

All Marijuana rejection letters have now been emailed out, with the exception of the ones highlighted below. I will be on leave Friday. Mike and Teneille will be around, and Leslie Mayer will be acting. Otherwise, we can address everything on Monday.

Everyone relax tomorrow!!

Heather.

From: Achbach, Heather E.
Sent: Wednesday, November 27, 2024 11:44 AM
To: Hamilton, Kerry R. <Kerry.R.Hamilton@dea.gov>
Cc: Kellstrom, Melissa A. <Melissa.A.Kellstrom@dea.gov>; Washington, Crystal L <Crystal.L.Washington@dea.gov>; Van Linn, Michael L. <Michael.L.Van.Linn@dea.gov>; Willenbring, Daniel <Daniel.Willenbring@dea.gov>; Mason, Teneille W <Teneille.W.Mason@dea.gov>
Subject: MJ letters with formatting errors

Kerry, Melissa, and Crystal,

As discussed Tuesday, there were a few of the Marijuana letters that weirdly formatted the name of the recipient. Those letters are attached.

Issues are as follows:

“Minorities for Medical Marijuana, Inc. Marijuana Rejection letters 11252024”

The address and salutation are different.

We think it should be this one:

Cannabis and Hemp for Minorities for Medical Marijuana. Minorities for Medical Marijuana, Inc.

Eric Foster

eric@m4mmunited.org

- “Veterans Action Council Marijuana Rejection letters 11252024”

We have an address for these individuals on the excel spreadsheet. No address on the letter. Up to you all if you want one on here.

Veterans Action Council

Apt 622

Greenbriar Circle Petaluma, CA 94954

Esaia González

soijana@proton.me; esaiaagonzalez@gmail.com

- “San Diego County Marijuana Rejection letters 11252024-“

San Diego County Kelly Anderson kellyjaninethequeen@gmail.com

This person does not represent the county of San Diego but signed her emails with those words, it went in the chart that way. Suggest reformat to address it to her.

- “Students for Sensible Drug Policy Marijuana Rejection letters 11252024“

There are 2 letters. One has an address but no email. It looks like it corresponds to this entry:

Students for Sensible Drug Policy - Robert T. Rush, counsel for 600 17th Street, Suite 2800 South, Denver, CO 80202

2nd Letter to Ms. Murti – presumably a member of the same organization as the letter to SSDP

Students for Sensible Drug Policy Kat Murti - kat@ssdp.org 1800 M St NW, #33051 Washington, DC 20036

Suggest addressing second letter only to Kat Murti to remove confusion.

- “American Academy of Child Marijuana Rejection letters 11252024” - American Academy of Child and Adolescent Psychiatry is cutoff, and the letter is addressed to American Academy of Child.

- Daniel Kyle’s letter doesn’t have any space between the address and salutation. Tech error if we want to rewrite.

- Joshua Taylor

graysonlichtenthaler@gmail.com

No address provided

we had the incorrect email address in the spreadsheet; correct email address is:

jtayt7@gmail.com.

Also, as an FYI, we had 14 letters we couldn't send as we had no email addresses. Those are:

- Joseph Garofalo Joseph Garofalo No e-mail provided 31 Dartmouth St., Keene, NH 03249
- Students for Sensible Drug Policy Robert T. Rush, counsel for SSDP No e-mail provided 600 17th Street, Suite 2800 South, Denver, CO 80202
- The Equity Trade Network Leah Weitz No e-mail provided 2261 Market St., #4, San Francisco, CA 94114
- Nicole Ricci (New York Small Farma Ltd) Pet. to Participate Nicole Ricci No e-mail provided 728 Broadway, Kingston, NY 12401
- Association of State Criminal Investigative Agencies C/O: Bureau of Criminal Investigation – Virginia State Police, Drew Evans, No e-mail provided 7700 Midlothian Turnpike, North Chesterfield, VA 23235
- Major Cities Chiefs Association Laura Cooper, Executive Director No e-mail provided P.O. Box 71690, Salt Lake City, UT 84171
- Major County Sheriffs of America Megan Noland, Executive Director No e-mail provided P.O. Box 81762, Rochester, MI 48308
- National Alliance of State Drug Enforcement Agencies Donald Payton, President No e-mail provided P.O. Box 16278, Austin, TX 78761
- National Association of Police Organizations William Johnson, Executive Director No e-mail provided 317 S. Patrick Street, Alexandria, VA 22314
- National District Attorneys Association Nelson Bunn, Executive Director No e-mail provided 1400 Crystal Drive, Suite 330, Arlington, VA 22202
- National HIDTA Directors Association C/O: Washington/Baltimore HIDTA, Mike McDaniel, President No e-mail provided 1800 Washington Blvd., Suite 150, Baltimore, MD 21230
- National Narcotic Officers' Associations' Coalition Eric Brown, President No e-mail provided 455 Massachusetts Ave., NW, Box 112, Washington, D.C. 20001
- Sergeants Benevolent Association NYPD Vincent Vallelong, President No e-mail provided 57 Leonard Street, New York, NY 10013
- Minority Cannabis Business Association (MCBA) Mike Lomuto, Board Chair No e-mail provided 1300 I Street, NW, Suite 400 E, Washington, D.C. 20005

Heather E. Achbach

Acting Section Chief

Regulatory Drafting & Policy Support (DPW)

Drug Enforcement Administration

Washington, D.C.

Desk: 571-387-3185 | Cell: 206-330-3920

www.deadiversion.usdoj.gov



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

UC San Diego's Center for Medicinal Cannabis Research
220 Dickinson St.
Suite B
San Diego, CA 92103
igrant@health.ucsd.edu

Dear UC San Diego's Center for Medicinal Cannabis Research,

This is in response to your request, for a hearing and/or to participate in a hearing, to the Drug Enforcement Administration (DEA) regarding the notice of proposed rulemaking (NPRM) to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) and 89 FR 70148 (Aug. 29, 2024).

Upon review and careful consideration, DEA has determined that the request did not sufficiently establish that you are an “interested person” under DEA regulations and/or the request did not sufficiently state with particularity the relevant evidence on a material issue of fact that you intended to present during the hearing. See 21 CFR 1300.01(b), 1308.44(a), 1308.44(b), 1316.47, 1316.48; see also Placement of Lorcasein Into Schedule VI, 78 FR 26701 (May 8, 2013); Placement of Lacosamide Into Schedule V, 74 FR 23789 (May 21, 2009); Rescheduling of the FDA Approved Product Containing Synthetic Dronabinol From Schedule II to Schedule III, 64 FR 35928 (July 2, 1999); Placement of Pemoline in Schedule IV, 40 FR 4150 (Jan. 28, 1975). Therefore, DEA has decided not to grant your request.

Sincerely,

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division

CERTIFICATE OF SERVICE

I certify that this document was filed with the Court via the court's electronic filing system, on the 17th day of February, 2025, and an electronic copy was served on all counsel of record via the CM/ECF system on the same date. I further certify that I have mailed the foregoing document via first class mail, postage paid, to those parties or their counsel who are not registered through the CM/ECF system.

/s/Austin T. Brumbaugh

Austin T. Brumbaugh